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Preface 
 
SKELETAL MUSCLE ATROPHY – the loss of muscle mass and function – is 
a growing problem in our over-aged and under-trained society.  
Either through ageing, disease or immobility, muscle wasting is always 
accompanied by a reduced quality of life and can lead to serious health 
problems.   
It was my personal interest to contribute to a possible solution of the problem 
of skeletal muscle atrophy, which has almost epidemical character since it is 
affecting every individual somehow throughout its life. With this master thesis my 
intention is to add a piece to the mosaic of knowledge which may in the end lead 
to a treatment of skeletal muscle loss.   
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1 ABSTRACT 
 
 Rationale: Skeletal muscle tissue is of essential importance for the human 
body and its deficiency can lead to severe health problems and a reduced quality 
of life. Its plasticity and sensitivity to the surrounding conditions may be a benefit 
in desirable conditions, but it also makes the skeletal muscle tissue attackable in 
critical situations. In case of muscle atrophy the balance between synthesis and 
degradation of proteins is destroyed. This results in a decrease in myofibre size 
leading to a decrease in total muscle mass. In critically ill patients, many chronic 
diseases (cancer, AIDS, etc.) as well as immobility and the physiological process 
of ageing an increased loss of skeletal muscle mass and strength was observed 
(Strasser et al., 2007). Interestingly, states of muscle loss are often accompanied 
by acute or chronic inflammation. Cell culture and animal models have shown 
that pro-inflammatory cytokines directly affect the insulin-like growth factor (IGF)-
1 system, one of the major regulators of skeletal muscle growth (Frost et al., 
2003; Frost et al., 2004). Recently, it has been discovered that miRNAs are also 
involved in ‘fine-tuning’ the expression of transcription factors and signalling 
mediators important for muscle biology, including the regulation of proliferation 
and the differentiation during myogenesis (Callis et al., 2008). Therefore, the aim 
of this study was to investigate to which extent the IGF-1 system, myogenic 
markers and miRNAs are directly influenced by inflammatory stimuli in skeletal 
muscle cells.  
Methods: Mouse C2C12 skeletal muscle myoblasts were differentiated to 
myotubes in vitro. Differentiation lasted for 4 days and mRNA expression of IGF-
1 splicing variants (IGF-1Ea, IGF-1Eb, MGF), myogenic differentiation markers 
(MyoD, Myogenin) and miRNAs (miR-1, -133a, -133b, -206, -499, -155) were 
analyzed by real-time qPCR at day 0 and day 4 for myoblasts as well as for 
myotubes. Myotubes were incubated with LPS (1µg/ml), TNF-α (10ng/ml), IL-6 
(10ng/ml) or vehicle for 0, 1, 3, 6, 12, 24 and 48h. At the indicated time-points, 
mRNA expression of IGF-1 splicing variants (IGF-1Ea, IGF-1Eb, MGF), myogenic 
differentiation markers (MyoD, Myogenin) and miRNAs (miR-1, -133a, -133b, -
206, -499, -155) were determined by real-time qPCR. IGF-1 and TNF-α protein 
concentration was measured in the supernatants after stimulation with LPS 
(1µg/ml), TNF-α (10ng/ml), or vehicle at the time-points 0, 1, 3, 6, 12, 24 and 48h, 
IL-6 protein concentration at the time-points 0, 12, 24 and 48h. Analyzes were 
performed via ELISA.  
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Results: During differentiation the myogenin expression increased 7-fold (p < 
0.05) while MyoD was not affected. We observed a 36-fold (p < 0.05) up-
regulation of IGF-1Ea and a 31-fold (p < 0.05) increase of MGF. IGF-1Eb 
expression level did not change. We detected a significant increase for miRNA-1 
to 464-fold (p<0.05), for miR-206 to 14-fold (p<0.001), for miR-133a to 461-fold 
(p<0.01) and for miR-133b to 17-fold (p<0.5), whereas the levels of miR-499 and 
miR-155 did not change. Compared to 0h TNF-α stimulation leaded to a 
significant reduction of MyoD level to 61 ± 6% (p<0.001) 12h after incubation, 
whereas LPS-treatment revealed no effect. Myogenin drops significantly to 39 ± 
15% (p<0.01) 12h after stimulation with TNF-α accompanied by a decrease of the 
control to 57 ± 12% (p<0.01). The expression level of IGF-1Ea decreased to 34 ± 
11 % (p<0.001) and of MGF to 32 ± 11% (p<0.001) 12h after TNF-α treatment. At 
this time-point MGF dropped significant to 58 ± 13% (p<0.05) after LPS-
treatment. IGF-1Eb levels decreased to 61 ±10% (p<0.01) after 12h of IL-6 
stimulation. The chosen inflammatory stimuli did not affect the here analyzed 
miRNAs. After 48h the IGF-1 protein concentration control increased significantly 
2.2-fold (p<001) in the control, 2.8-fold after LPS incubation (p<0.01) and 1.4-fold 
after IL-6 incubation (p<0.05). TNF-α stimulation showed no significant effect. 
TNF-α protein concentration increased only after TNF-α stimulation, IL-6 protein 
concentration only after IL-6 stimulation.  
Conclusion: In our study we have shown that muscle regulatory genes, which 
are enhanced before and / or during differentiation, are directly influenced by 
TNF-α. Muscle-specific miRNAs as well as the immune-related miRNA-155 seem 
not to be involved in this interaction, although they are enhanced up to 400-fold 
during differentiation. The results from this study contribute to improve the 
knowledge about the mechanisms leading to skeletal muscle atrophy during 
inflammatory conditions.  
 
1.1 Zusammenfassung 
 
Rationale: Die Skelettmuskulatur ist von essentieller Bedeutung für den 
menschlichen Körper und ein Defizit kann zu ernstzunehmenden 
gesundheitlichen Schäden bzw. einer reduzierten Lebensqualität führen. Ihre 
Plastizität und Sensitivität der Umwelt gegenüber ist unter günstigen 
Bedingungen eine wünschenswerte Eigenschaft, macht das Gewebe aber auch 
gleichzeitig angreifbar in kritischen Situationen. Im Falle einer Muskelatrophie ist 
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die Balance zwischen Synthese und Abbau von Proteinen gestört. Das führt zu 
verringerter Muskelfasergröße und, daraus resultierend, zu einer verringerten 
totalen Muskelmasse. Bei kritisch kranken Patienten und vielen chronischen 
Erkrankungen wie Krebs, AIDS usw. sowie Immobilität und dem physiologischen 
Alterungsprozess kommt es zu einem gesteigertem Verlust der Muskelkraft und –
masse (Strasser et al., 2007). Interessanterweise werden Zustände des 
Muskelverlustes oft begleitet vom Auftreten einer akuten oder chronischen 
Inflammation. Zellkultur und Tierversuchsmodelle haben gezeigt, dass 
proinflammatorische Zytokine direkt das Insulin-like growth factor (IGF)-1 system, 
einen der Hauptregulatoren des Skelettmuskelwachstums, beeinflussen (Frost et 
al., 2003; Frost et al., 2004). Kürzlich wurde gezeigt, das miRNAs ebenfalls 
involviert sind im ‘Fine-Tuning’ der Expression der Transkriptionsfaktoren und 
Signalmediatoren wichtig für die Muskelbiologie, eingeschlossen der Regulation 
der Proliferation und der Differenzierung während der Myogenese (Callis et al., 
2008). Das Ziel dieser Studie ist es darum festzustellen, in welchem Umfang IGF-
1 system, Muskelmarker und miRNAs direkt durch die Inflammation beeinflusst 
werden.  
Methodik: Maus C2C12 Skelettmuskelmyoblasten wurden in vitro zu 
Myotubes differenziert. Die Differenzierung dauerte 4 Tage und die Expression 
der mRNA der IGF-1 Splicingvarianten (IGF-1Ea, IGF-1Eb, MGF), der 
Muskeldifferenzierungsmarker (MyoD, Myogenin) und der miRNAs (miR-1, -
133a, -133b, -206, -499, -155) wurde mittels real-time qPCR an den Tagen 0 und 
4 sowohl für Myoblasten als auch für Myotubes gemessen. Die Inkubation der 
Myotubes erfolgte mit LPS (1µg/ml), TNF-α (10ng/ml), IL-6 (10ng/ml) oder vehicle 
für 0, 1, 3, 6, 12, 24 und 48h. An den angegebenen Zeitpunkten wurde die 
Expression der mRNA der IGF-1 Splicingvarianten (IGF-1Ea, IGF-1Eb, MGF), 
der Muskeldifferenzierungsmarker (MyoD, Myogenin) und der miRNAs (miR-1, -
133a, -133b, -206, -499, -155) mittels real-time qPCR gemessen. Die IGF-1 und 
TNF-α Proteinkonzentrationen im Überstand  wurden nach Stimulation mit LPS 
(1µg/ml), TNF-α (10ng/ml), oder vehicle an den Zeitpunkten 0, 1, 3, 6, 12, 24 und 
48h, die IL-6 Proteinkonzentration an den Zeitpunkten  0, 12, 24 und 48h via 
ELISA bestimmt 
Resultate: Im Laufe der Differenzierung stieg die Expression von Myogenin 
um das 7-fache (p < 0.05) während MyoD nicht beeinflusst wurde. Wir konnten 
einen 36-fachen (p < 0.05) Anstieg von IGF-1Ea und einen 31-fachen (p < 0.05) 
Anstieg von MGF beobachten. Das Expressionslevel von IGF-1Eb blieb 
unverändert. Wir detektierten eine signifikante Zunahme der miRNA-1 auf das 
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464-fache (p<0.05), für miR-206 auf das 14-fache (p<0.001), für miR-133a auf 
das 461-fache (p<0.01) und für miR-133b auf das 17-fache (p<0.5), während die 
Level der miR-499 und miR-155 keine Veränderungen zeigten. TNF-α 
Stimulierung führte, verglichen mit 0h, zu einer signifikanten Reduktion des MyoD 
Levels zu 61 ± 6% (p<0.001) 12h nach der Inkubation, während die LPS Zugabe 
keinen Effekt zeigte. Die Myogeninexpression fiel signifikant auf 39 ± 15% 
(p<0.01) 12h nach der Stimulation mit TNF-α, was begleitet wurde von einem 
Abfall in der Kontrolle auf 57 ± 12% (p<0.01). IGF-1Ea sank auf 34 ±11% 
(p<0.001) und MGF auf 32 ± 11% (p<0.001) 12h nach TNF-α Zugabe. Zu diesem 
Zeitpunkt konnten wir auch eine signifikante Herabregulation von MGF auf 58 ± 
13% (p<0.05) nach LPS Stimulation verzeichnen.  Das IGF-1Eb Expressionslevel 
fiel ab auf 61 ± 10% (p<0.01) nach 12h IL-6 Stimulation. Die verwendeten 
inflammatorischen Stimuli hatten keinen Einfluss auf die hier analysierten 
miRNAs. Die IGF Proteinkonzentration stieg signifikant nach 48h 2.2-fach 
(p<001) in der Kontrolle, 2.8-fach nach LPS Inkubation (p<0.01) und 1.4-fach 
nach IL-6 Inkubation (p<0.05). Die TNF-α Stimulation zeigte keinen signifikanten 
Effekt. Eine TNF-α Proteinkonzentration war nur in den mit TNF-α stimulierten 
Proben messbar, eine IL-6 Proteinkonzentration nur in den mit IL-6 stimulierten. 
Fazit: In unserer Studie haben wir gezeigt, dass Muskelregulatorgene, welche 
vor und / oder nach der Differenzierung erhöht sind, direkt durch TNF-α 
beeinflusst werden. Muskelspezifische miRNAs und die immunsystembezogene 
miRNA-155 scheinen bei dieser Interaktion, trotz ihres bis zu 400-fachen 
Anstiegs während der Differenzierung nicht involviert zu sein. Die Resultate 
dieser Studie tragen zu einer Erweiterung des Wissens über die Mechanismen, 
welche einer durch inflammatorische Bedingungen induzierten 
Skelettmuskelatrophie zu Grunde liegen bei.   
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2 INTRODUCTION 
 
2.1 Skeletal muscle 
 
Muscle tissue is one of the basic tissues in the human body. There are three 
types of muscle in the vertebrates: Skeletal muscle, cardiac muscle and smooth 
muscle. Skeletal muscle is one specialized form of muscle tissue. It shows 
similarities to the other muscle tissues in many fields, but it also differs in some 
main points to fulfil its unique functions.  
Skeletal muscle tissue consists of long cells which have the ability to contract 
and it is primary required for locomotory functions and maintaining posture. 
Besides it is also needed for other essential physiological mechanisms, such as 
breathing. Skeletal muscles are normally under the control of the conscious 
which, beside structural differences, also distinguishes them from cardiac and 
smooth muscles. Beside these primary functions, the skeletal muscle tissue 
serves also as the biggest resource for amino acids and nitrogen in the body and 
the maintenance of muscle mass is therefore under strict metabolic control 
(Wolfe, 2006).   
Skeletal muscles consist of muscle bundles which are composed of long 
multinuclear cells, called myofibres. Myofibres develop from fused mononuclear 
cells in the late embryonic period. Their nuclei are located peripherally just 
beneath the cell membrane (sarcolemma). Each of these myofibres itself consists 
of myofibrils containing two types of filaments, the thin actin filament and the thick 
myosin filament. These filaments are building the functional basis of the myofibril, 
the sarcomeres. The shortening of the sarcomeres allows the muscle to contract. 
Due to the sarcomeres, which let the muscle appear in dark and light bands, 
skeletal muscle is also called “striated”. Connective tissue supports the formation 
of the muscle: a muscle fibre is surrounded by the endomysium, a muscle fibre 
bundle (also known as fascicles) by the perimysium and the muscle itself by the 
epimysium (Campell, 2000) (Fig. 2-1).  
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Figure 2-1: Muscle structure (National_Institutes_of_Health, 2000; 
National_Institutes_of_Health, 2010) 
 
Muscle contraction is controlled by Calcium. If the Ca2+ level is low, the 
Troponin – Tropomyosin complex inhibits the interaction between Actin and 
Myosin. A high Ca2+ concentration effects the conformation of Troponin and 
activates the energy producing ATPase. Both is required to let Myosin interact 
with actin, leading to a contraction of the muscle (Campell, 2000).  
 
2.1.1 Fibre types 
 
Skeletal muscles can be divided in subtypes, each consisting of different fibre 
types. Due to its fibre type composition, a muscle develops different contractile 
characteristics. There are four fibre types known, which differ mainly in their 
myosin heavy chain (MHC) which itself is a part of the myosin filament. It was 
observed that the MHC protein expressed in a single muscle fibre is related to its 
maximum contraction velocity and that the MHC based fibre type composition of 
a muscle can be used to predict its contractile properties (Talmadge and Roy, 
1993).  
Type 1 MHC (β-MHC) can be found in the oxidative slow twitch type of 
muscle, which contracts slowly but can hold its contraction over a long period. 
These oxidative muscles possess characteristically a great amount of 
mitochondria.  
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The other three subtypes are fast twitch types, namely MHC type 2a, 2x and 
2b. Fast type muscles are able to contract quickly and to create more force than 
the slow type, but they can hold the tensed state only for a short time. Type 2x 
and 2b are anaerobic muscles and develop the greatest amount of force 
(McCarthy et al., 2009).   
Every human individual has a genetically predisposition for the amount of slow 
and fast type muscles. Nevertheless through a fibre type switch the muscle tissue 
is partly able to adapt to changed environmental conditions and requirements. 
This adaptation is also linked to the process of ageing and muscle atrophy. A 
fibre type transition from slow to fast for example is associated in humans with 
unloading and was observed in bed resting individuals  as well as such in space 
flights (Trappe et al., 2009). 
It was observed, that the Calcineurin - NFAT pathway is involved in fibre type 
specification and a slow motor neuron activity is supposed to activate this 
signalling transduction cascade which leads to the expression of slow oxidative 
muscle genes (Tothova et al., 2006). The authors describe NFAT as a nerve 
activity sensor in skeletal muscle fibres.  
 
2.1.2 Development 
 
During embryology muscle tissue develops from the paraxial mesodermal 
layer of embryonic germ cells. This mesoderm is divided into somites, which 
divide themselves into sclerotome, dermatome and myotome (muscle 
development). The myoblasts (muscle progenitor cells) can remain in the somits 
and form all muscles connected to the vertebral column or they move out into the 
body following chemical signals to build up all other muscles (Hirano et al., 1995).   
 
2.1.2.1 Myogenic markers 
 
Beside embryological development there is a life-long synthesis of new 
muscle cells. Myogenic markers are proteins specifically expressed in muscle 
cells. They play an essential role in the molecular regulation of muscle growth 
and their expression level depends on the developmental and differentiation state 
of the cell. MyoD family of myogenic transcription factors and MEF2 family of 
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MADS-box transcription factors play a central role in controlling myogenesis 
(Goldspink et al., 2008) (Fig. 2-2).  
MyoD and its relatives are also called myogenic regulatory factors (MRFs). In 
the past few years, studies concentrated mainly on four of its members: MyoD, 
Myf5, myogenin and MRF4. MyoD belongs to a class of DNA binding proteins 
with a basic helix-loop-helix domain (bHLH). Promoters and enhancers of muscle 
specific genes contain a specific binding site for MRFs, the so called E boxes. 
The MRF necessary for a certain differentiation and developmental state binds to 
its consensus sequence to start transcription (Heidt et al., 2007).  
The early Notch, Wnt and sonic hedgehog signalling in the embryo switches 
on the expression of Myf5 and MyoD in the somites (Buckingham, 2001). While 
these two MRFs are essential for the start of the myogenic lineage, myogenin 
can be seen as the “terminal differentiator”.  
 
Figure 2-2: Muscle stem cell differentiation (Goldspink et al., 2008) 
 
MyoD regulates the expression of myogenin and other genes important for 
muscle development, for example myosin heavy and light chains and M-
cadherin. Another important regulatory effect of MyoD showing its relevance for 
differentiation is the up-regulation of cyclin-dependent kinase inhibitor p21, which 
causes an irreversible exit of the differentiating cells from the cell cycle (Halevy et 
al., 1995). Beside these activating effects, MyoD has also been shown to 
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suppress genes which expressions are related to a myogenic phenotype. It was 
demonstrated that MyoD induces miRNA-206, which as a result directly targets 
specific sequences and suppresses the expression of the genes Fstl1 and Utrn, 
both genes associated with the muscle precursor cell (Rosenberg et al., 2006).  
Myogenin is located downstream of the early indicators Myf5 and MyoD. It 
seems that MyoD is unable to fulfil the terminal differentiation program because 
its functions are suppressed by in vivo signalling events. This might be the 
reason why myogenin, which shows no reaction on these suppressive signals, 
execute the terminal differentiation program instead of MyoD (Tapscott, 2005) 
In contrast to the MyoD family, the Mef2 proteins belong to the MADS box-
containing transcription factor family. Their spectrum of activity is broader than 
that of the MyoD family and also includes other developmental functions beside 
muscle development. Mef2 seems to assist MyoD and it has been found that E 
boxes and Mef2 binding sites are localized close to each other (Wasserman and 
Fickett, 1998). As the appearance of respective myogenic regulatory factors is 
tightly controlled during differentiation of muscle cells from myoblasts to 
myotubes, they can serve as “myogenic markers” to describe a certain 
differentiation state.  
It has been shown that during cultivation of skeletal myoblasts there is no 
initiation of differentiation as long as proliferation continues. After leaving the cell 
cycle, myoblasts start to express muscle specific proteins like actine, myosin, 
tropomyosin and muscle specific enzymes. Although myoblasts are already 
expressing MyoD and Myf-5, they continue to proliferate in the presence of 
growth promoting proteins. It needs at least one other stimulus to make the cells 
leaving the cell cycle. Here the crucial factors are a decrease of the cell cycle 
activators (e.g. cyclins and cdks) and an increase of inhibitors of the cell cycle 
(e.g. p21, Rb, p57 and p27). This process seems to be partly under the control of 
MyoD. Interestingly the level of MyoD changes during cell cycle phases. The 
relevant step in muscle cell differentiation, the exit of the cell cycle, takes place in 
the G1 phase, when MyoD is maximally expressed. In contrast Myf5 is down 
regulated at this time. During non-differentiation phases (G0, G1 to S-phase 
transition) MyoD is down- and Myf5 is upregulated (Kitzmann and Fernandez, 
2001) (Fig. 2-3).  
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Figure 2-3: MyoD and Myf5 levels during the cell cycle (Kitzmann and 
Fernandez, 2001) 
 
An importent actor during muscle differentiation is the Retinoblastoma Protein 
(Rb) (see Fig. 2-4). Entrance into the S Phase is achieved through 
phosphorylation of Rb catalysed by cyclin dependent kinases. This 
phosphorylation activates the E2F1-3 transcription factors which are responsible 
for gene expression of cell cycle progression associated genes. In a non 
phosphorylated state the Rb protein blocks the cell cycle (Coller, 2007).   
 
Figure 2-4: Acting of retinoblastoma protein in muscle cell differentiation 
(Coller, 2007) 
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After leaving the cell cycle, the myoblasts are able to differentiate and to fuse 
to form the multinucleate myotubes. Although it is known that muscle cell 
differentiation is controlled by external signals and interactions between various 
transcribtion factors, the detailed molecular mechanisms leading to terminal 
differentiation are still under investigation.  
 
2.2 Skeletal muscle plasticity 
 
The ability of the skeletal muscle tissue to adapt to special needs and to 
changed conditions is a result of its ability to react on environmental stimuli. In 
addition to environmental causes, every individual is influenced by its special 
characteristics as genetic predisposition, age, health and gender.  
To adapt to the various conditions, muscle gene expression during synthesis 
and degradation is regulated at the transcriptional and translational level. A 
change in gene expression is caused by a variety of factors influencing different 
pathways responsible for muscle atrophy and hypertrophy, respectively.  
 
2.2.1 Muscle hypertrophy 
 
Both, external and internal anabolic stimuli are influencing skeletal muscle 
growth. The two most common external factors, playing together in regulating 
skeletal muscle mass, are the mechanical load (training) on the one hand and the 
nutrition on the other hand. The unique genetic predisposition of every individual 
enhances or constrains - same as the internal components - the reactivity of the 
muscle on growth related stimulation.  
 
2.2.1.1 Insulin-like growth factor (IGF) signalling pathway 
 
The body uses so called growth factors, to give positive signals for cell 
division, maturation, differentiation and other processes necessary for growth.  
One of the most important growth factors which play a crucial role in the 
development of the organism is the insulin like growth factor (IGF) family. IGF as 
other hormones are part of a complex system cells use to communicate with the 
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surrounding. While IGF-2 is important for the prenatal growth, IGF-1 influences 
prenatal as well as postnatal growth. Although IGF-1 is primary produced in the 
liver mainly after stimulation with the growth hormone Somatotropin (systemic 
IGF-1), it can also be built extra hepatic in a variety of tissues (autocrine IGF-1) 
and is as well of essential importance for muscle development. The insulin-like-
growth factor signalling pathway is known for  regulating protein synthesis and 
the activation of this pathway by IGF-1 or related molecules leads to skeletal 
muscle fibre growth and hypertrophy (Goldspink, 2004). Besides it was described 
that an increase in muscle load correlates with an increase of IGF-1 expression 
(Jacinto and Hall, 2003).   
The IGF-1 gene itself includes six exons and was found to be expressed 
through alternative splicing. The liver IGF-1 starts its transcription normally at 
exon two, whereas IGF-1 expression in other tissues is initiated at exon 1 
(Harridge, 2003).  
 
 
Figure 2-5: The IGF-1 splicing variants (Goldspink, 2004)  
 
Depending on external signals (mechanical, hormonal) the IGF-1 gene is 
alternatively spliced to IGF-1Ea, IGF-1Eb and MGF (IGF-1Ec) (Fig. 2-5). In the 
resting muscle only IGF-1Ea is expressed. After exercise or muscle damage the 
muscle reacts over alternative splicing (reading frame shift) with the expression of 
the mechanical growth factor (MGF) which is sensitive to mechanical signals. In 
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case of damage, MGF is involved in the activation of muscle satellite cells which 
are essential in the regeneration process (Goldspink, 2003).  
The IGF1-Eb splicing variant is mentioned in literature (Philippou et al., 2009), 
but its special modes of acting are not known up to date. However, in contrast to 
MGF, which is thought to play a role in activation and proliferation, IGF-1Eb was 
proven to be up-regulated together with IGF-1Ea in relation to differentiation 
(McKay et al., 2008).   
A decrease of circulating levels of GH and IGF-1 was proven with increasing 
age and elderly individuals show a reduced up-regulation of MGF in response to 
exercise (Goldspink, 2004). If there is a closer connection of the age-related 
change in the expression level of IGF-1Ea and MGF to sarcopenia, remains to be 
discovered.  
 
2.2.1.2 IGF-1 and mTOR  
 
IGF-1 is an anabolic agent with many functions like insulin. It regulates for 
example the glucose uptake and the DNA / RNA synthesis and stimulates the AS 
uptake (Binoux, 1995). As mentioned above, IGF1 is important for muscle 
metabolism by increasing protein synthesis and inhibition of protein proteolysis.  
IGF1 was shown to act mainly over the PI3K / protein kinase B (AKT) / 
mammalian target of Rapamycin (mTOR) pathway which is thought to sense and 
integrate environmental signals to control protein translation (Fig. 2-6). The 
mTOR pathway is of great importance for muscle development, but it also plays a 
role in cancer and metabolic diseases. mTOR is part of two different complexes, 
the mTORC1 and the mTORC2. mTORC1 contains the regulatory associated 
protein of mTOR (raptor), which is sensitive to rapamycin. Instead of this protein 
mTORC2 contains the rapamycin-insensitive companion of mTOR (rictor). The 
two complexes carry out different functions.  
mTORC1 acts primary over inhibition of 4E-BP1, leading to activation of the 
translation factor eIF4E and the formation of the eIF4E complex needed for 
ribosomal assembly. mTORC1 also acts over activation of p70S6k, which then 
phosphorylates rpS6. Through these major targets mTORC1 is able to regulate 
muscle mass development by controlling the initiation of protein translation.  
The major function of mTORC2 in the mTOR pathway is the activation of 
PKB/Akt. Akt itself was already described in literature to increase the cross 
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sectional area of skeletal muscle fibres by further signalling transduction (Glass, 
2005).  
Akt1 is responsible for the phosphorylation status of the Foxo family of 
transcription factors. If Foxo is phosphorylated by Akt1, it leaves the nucleus and 
becomes inactive, thereby preventing the induction of atrophy. It was shown that 
not only mTOR, but also the Calcineurin / NFAT pathway is induced by IGF-1 and 
it was suggested that Calcium is able to couple a mechanical stimulus to the IGF-
1 pathway (Jacinto and Hall, 2003) (Fig. 2-6). As mentioned above, NFAT was 
already described as a nerve activity sensor in skeletal muscle and therefore an 
activation of this pathway by IGF-1 seems to be also interesting in the context of 
fibre-type switch.  
 
 
Figure 2-6: IGF-1 induced skeletal muscle hypertrophy (Jacinto and Hall, 2003)  
  
2.2.1.3 IGF-1 and satellite cells 
 
Satellite cells are proliferating skeletal muscle cells responsible for 
regenerating muscle tissue in response to injury or after increased loading 
conditions.  
These small mononucleated skeletal muscle stem cells are located between 
the basal lamina of the muscle and the sarcolemma of myofibres. After their 
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activation, the satellite cells differentiate into myoblast-like cells, which are able to 
fuse with each other to form new myofibres. It is also possible that these 
myoblasts become incorporated into existing myofibres in case of damage 
(Bischoff, 1989).  
 
 
 
Figure 2-7: Activation of satellite cells (Anderson, 2000) 
 
According to Anderson et al, in a damaged muscle which is normally 
accompanied by a damage of the sarcolemma, the depolarization during muscle 
contraction goes not hand in hand with a repolarisation afterwards (Anderson, 
2000). This results in an immense shear, which causes increased synthesis of 
reactive nitrogen species (such as NO) which leads in cooperation with the 
hematopoietic growth factor (HGF) to an activation of quiescent satellite cells.  
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Another important factor for satellite cell development is the insulin-like growth 
factor 1, which has been shown to promote the proliferation, differentiation and 
fusion of satellite cells in primary cultures (Chambers and McDermott, 1996). 
IGF-1 therefore is thought to contribute to a hypertrophy response through 
stimulation of the proliferation of satellite cells.  
 
2.2.2 Muscle atrophy 
 
The maintenance of muscle mass involves a multitude of signalling 
mechanisms keeping protein synthesis and degradation in balance. Atrophy is 
caused by a disturbed balance in which protein degradation takes overhand. 
Therefore, atrophy can be a result from reduced protein synthesis, increased 
degradation, or both. Generally muscle atrophy is characterised by a decrease in 
myofibre size leading to a decrease in total muscle mass. It can be distinguished 
between physiological and pathological occurrences. 
 
2.2.2.1 Physiological forms of muscle atrophy 
 
The physiological form of muscle atrophy is also known as sarcopenia. It 
occurs in elderly and is characterized by a loss of muscle mass and strength. 
Seventy to 80 years old people lose an average of 20-30% of their total muscle 
mass and this decrease continues at the rate of 1 % - 2 % a year. The loss of 
muscle mass is accompanied by a reduced strength, which falls to a level of 30 – 
40 % of that from young individuals (Porter et al., 1995).  
The detailed mechanisms leading to this form of atrophy remain to be 
discovered. However, recent examinations suggest a close connection between 
loss of muscle mass in elderly individuals and a reduced number and activation 
of satellite cells, a decreased muscle protein synthesis, increased oxidative 
stress and changes in the glucose metabolism (Bruunsgaard and Pedersen, 
2003).  
Also a change in fibre type composition from slow to fast was described to be 
associated with age-related muscle loss, as well as hormonal changes, or the 
replacement of muscle by connective and adipose tissue (Lee et al., 2007).  
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Also the genetic influence in age related muscle-loss becomes more and more 
a focus in research. One of the best studied genes for sarcopenia is the vitamin 
D receptor (VDR) which plays a key regulatory role in calcium homeostasis and 
skeletal muscle function. Endo et al. found out that the muscle fibres of VDR null 
knock-out mice were smaller and the expression level of early markers of 
myogenic differentiation was significantly higher compared with the controls 
(Endo et al., 2003). In addition to these findings a specific genotype of the 
Vitamin D receptor (VDR), the FokI genotype, was reported to be associated with 
a decreased muscle mass and strength. Individuals with this gene polymorphism 
showed a 2-fold higher risk to develop sarcopenia (Roth et al., 2004).  
 
2.2.2.2 Pathological forms of muscle atrophy 
 
The pathological form of muscle atrophy accompanies a lot of diseases, e.g. 
cancer, AIDS, cachexia, sepsis, chronical diseases and burn injury. Loss of 
skeletal muscle mass is also a common feature in conditions associated with 
immobility as for example in critically ill patients. The percentage of total muscle 
loss can be at a very high level (e.g. 13% for immobility, 30% in cancer). Muscle 
atrophy can cause post surgical complications and is often responsible for a 
prolonged recovery phase and hospitalization.  
Cachexia is one form of pathological muscle loss, which occurs during sepsis, 
AIDS, trauma as well as in cancer patients. It can be described as a wasting 
syndrome of skeletal muscle tissue and adipose tissue in connection with severe 
injury, chronic or end-stage malignant or infectious diseases (Jespersen et al., 
2006). As inflammatory cytokines influence cachexia, it was suggested, that a 
possible change in myogenic expression level caused by TNF-α may contribute 
to cachexia-related muscle wasting (Larsen et al., 2008).  
 
Both, the pathological and the physiological form of skeletal muscle atrophy 
are suggested to be regulated partly by components of the immune system as 
they are associated with inflammatory processes in the body (Frost et al., 2003).   
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2.2.2.3 Protein degradation 
 
Muscle atrophy caused by protein degradation involves at least three 
degradation systems which help the muscle to adapt to various conditions and 
provide amino acids and nitrogen in case of higher needs (e.g. diseases).  
One of the degradation pathways being proven to take part in causing 
proteolysis in case of activation is the evolutionary well conserved ubiquitin-
proteasome pathway (Fig. 2-8). The most important enzymes leading to 
proteasome mediated protein degradation are the E1 ubiquitin-activating 
enzyme, the E2 ubiquitin-conjugating enzyme and the E3 ubiquitin-ligating 
enzyme. These three enzymes work together to attach ubiquitins to the target 
protein. Now the 26S proteasome is able to recognize and to degrade the 
ubiquitin marked protein (Diao et al., 2008).  
 
 
Figure 2-8: Ubiquitin proteasome protein degradation system (Diao et al., 2008) 
 
E3 was shown to possess substrate specificity. In case of muscle protein 
degradation two genes were identified to encode E3 ubiquitin ligases: the muscle 
ring finger 1 (MuRF1) and the muscle atrophy F-box (MAFbx). The expression of 
both genes increased significantly in experimental models of skeletal muscle 
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atrophy. MuRF1 and MAFbx are expressed in response to NfkB activation 
(Bodine et al., 2001).  
The ubiqitin-proteasome pathway seems to be the most important protein 
degrading system in skeletal muscle atrophy. However, its actions are limited to 
abnormal muscle fibres. Muscle fibres which are intact cannot be accepted for 
degradation without the help of two other degradation systems, the lysosomal 
proteases and the calpains (Jackman and Kandarian, 2004).  
 
2.2.3 Skeletal muscle energy metabolism 
 
2.2.3.1 Calcium signalling pathway 
 
Skeletal muscle fibre type switch seems to be regulated by a calcium 
signalling pathway, involving calcineurin and the peroxisome proliferators-
activated receptor-gamma coactivator 1alpha (PGC-1alpha) (Fig. 2-10). One key 
fat burning molecule mediating long-chain fatty-acid beta-oxidation is the 
peroxisome proliferators-activated receptor (PPAR)delta, which was also proven 
to play an essential role in fibre type switch. PPAR, which was suggested as a 
possible downstream transcription factor of the calcineurin pathway, is activated 
primarily by fatty acids and their metabolites. Activation of PPARdelta enhances 
the expression of type 1 fibre contractile proteins and increases the mitochondrial 
biogenesis and the number of oxidation enzymes (Wang et al., 2004).  
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Figure 2-9: Effect of exercise training on skeletal muscle metabolism (Rockl et 
al., 2008) 
 
PPARdelta is also associated with high levels of UCP3 expression, which 
goes confirm with the discovery of a PPAR response element on the UCP3 gene 
promoter (Riquet et al., 2003).  
 
2.2.3.2 Uncoupling proteins 
 
The uncoupling proteins (UCPs) 1, 2 and 3 play an important role in energy 
metabolism. As mitochondrial inner membrane transporters they can act over 
uncoupling the ATP synthesis by dissipating the proton gradient. This leads to 
thermogenesis and to a decrease in ATP synthesis (Fig. 2-11). UPCs have been 
described in a variety of species, from animals to plants. Recent findings showed 
also an involvement in myogenesis. Chen et al. examined the expression of 
UPC2 in C2C12 cells on the transcriptional and the translational level. Although 
they detected UPC2 mRNA they were not able to measure any protein, which let 
them suspect a post-transcriptional regulatory mechanism. In their studies they 
observed a connection of the presents of MyoD and the expression of skeletal 
muscle specific UCP3 as well as UCP2. During myogenesis MyoD seems to up-
regulate UCP3 together with miRNA-133a. UCP2 translation is inhibited by 
miRNA-133a (Chen et al., 2009).  
 
 - 27 - 
 
Figure 2-10: Uncoupling the ATP synthesis over uncoupling proteins in the 
mitochondrial membrane (Collins et al., 2001) 
 
2.2.3.3 AMPK 
 
AMP-activated protein kinase is a kinase with a key role in energy metabolism 
which reacts on a change in the AMP/ATP ratio. Its function is conserved in all 
eukaryotes. Low ATP levels, occuring during exercise, induce the activation of 
AMPK, which then up-regulates the oxidative metabolism. As recently 
discovered, AMPK and PPARdelta, which are both up-regulated during exercise, 
collaborate in reprogramming skeletal muscle transcription and endurance 
(Narkar et al., 2008) (Fig 2-10).   
 
2.2.3.4 Starvation 
 
Starvation condition is a stress situation for the body and has a serious impact 
on the skeletal muscle tissue metabolism. Pyruvate dehydrogenase kinase (PDK) 
4 protein plays a key role during starvation. It is regulated by insulin and is 
involved in regulating the level of blood glucose. High levels of PDK4 were shown 
to decrease the activity of the pyruvate dehydrogenase and that this would down- 
regulate the consumption of carbohydrates in skeletal muscle during starvation 
(Majer et al., 1998).  
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As recently discovered, FOXO gene expression plays a regulatory role during 
nutrition depletion (Furuyama et al., 2003). According to the authors, especially 
FOXO1 showed in connection with PDK4 a remarkable increase during 
starvation. They also described a possible enhancing effect on the metabolic shift 
from glucose to fatty acid metabolism in skeletal muscle via FOXO1.  
 
2.2.3.5 Nutrition 
 
Nutritional supplements showing to regulate skeletal muscle mass are for 
example essential amino acids and carbohydrates. A broad spectrum of literature 
describes an influence of amino acids on muscle protein synthesis.  
As mechanical signals, nutrients can act over the mTOR pathway, but they are 
also able to activate transcription and initiate protein synthesis directly via an 
mTOR independent pathway (Kimball and Jefferson, 2004).  
Recently research concentrates also on the branched-chain amino acids, as 
leucine, valine or isoleucine. Leucine was found to act as a signal for accelerating 
protein synthesis (Matsakas and Patel, 2009).  
The activation of mTOR over nutrition supplements, as amino acids, seems to 
contribute to signalling transduction and to optimized protein syntheses. Amino 
acids are suggested to activate mTORC1 over the inhibition of TSC1-TSC2 or the 
stimulation of Rheb. It was proposed that amino acids lead to a conformational 
change within the mTORC1 so that the complex is able to interact with its targets. 
At the end of this pathway the phosphorylation of the p70S6k and rpS6 
stimulates protein synthesis (Wullschleger et al., 2006).   
Another interesting finding points out a possible difference between nutritional 
and growth factor signalling transduction after mTOR activation. It was observed 
that amino acid-induced rapamycin signalling seems to act only over mTORC1 
and is therefore completely independent of PKB and PI3K activation (Hornberger 
and Chien, 2006) (Fig. 2-6).  
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2.3 Crosstalk between skeletal muscle tissue and 
immune system 
 
In physical activity, muscle damage, pathological conditions as well as ageing 
the muscle corresponds to actions of the immune system. Cells of the immune 
system, as leukocytes, and pro- and anti-inflammatory cytokines are players of 
the immune system often mentioned in association with muscle atrophy. 
Especially proinflammatory cytokines, as TNF-α and IL-6 are closely linked to 
age-related muscle loss and they were shown to contribute to sepsis-induced 
atrophy (Callahan and Supinski, 2009).  
It was proven that skeletal muscle cells are sensitive to these immunological 
signals. Skeletal muscle cells can react on systemic inflammatory stimuli, but 
they are also able to express various cytokines themselves. 
Cell culture experiments have shown that bacterial lipopolysaccharide directly 
up-regulates pro-inflammatory cytokines in skeletal muscle cells via toll like 
receptors 2 and 4 and an experimental animal model revealed that LPS causes a 
drop of insulin-like growth factor (IGF)-1 which may contribute to muscle loss 
(Frost et al., 2003; Frost et al., 2004).  
 
2.3.1 LPS recognition by Toll-like receptors (TLRs)  
 
Lipopolysaccharide (LPS) is a cell wall component of gram negative bacteria, 
often used in trials to simulate an infection with this type of bacteria. It is 
recognized by Toll-like receptor 4 (TLR4), which then induces the immune 
response. TLRs are one type of cell-associated pattern recognition receptors 
specialized to recognize pathogen-associated molecular patterns (PAMPs). Over 
PAMPS the body is able to react on a pathological invasion by activation of the 
immune system and stimulation of cytokine release. TLRs are localized in the 
plasma (TLR1,-2,-4,-5,-6) or endosomal (TLR3,-7,-8,-9) membranes of various 
cell types. The different TLRs recognize specific molecules. TLR2 appears often 
in combination with either TLR1 or TLR6 and is known to react on molecules of 
gram positive bacteria. TLR7 and 8 are both sensitive for viral single stranded 
RNA. TLR9 is specialized on viral and bacterial unmethylated CpG DNA. 
Molecules of gram negative bacteria, as LPS, are recognized by TLR4. A muscle 
cell is able to react on LPS stimulation as TLRs are also expressed on the 
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surface of skeletal muscle cells. An expression of TLR1-7, but not TLR8 and 
TLR9 was observed in mouse skeletal muscle as well as in C2C12 cells (Frost et 
al., 2006).  
 
2.3.1.1 NF-kB signalling pathway 
 
Experiments with C2C12 myocytes showed that LPS activates the NF-kB 
signalling transduction which results in  increased expression of proinflammatory 
cytokines (Frost et al., 2006).  
NF-kB is an important signalling pathway in protein degradation and is 
followed by the activation of the mitogen-activated protein kinase (MAPK) 
pathways leading to skeletal muscle atrophy. NF-kB can be activated by a great 
spectrum of stimuli, such as growth factors, cytokines, viral and bacterial 
infections, oxidative and biomechanical stresses and others. In skeletal muscle, 
NF-kB activation occurs mainly as a response to a disease situation. It leads to 
muscle atrophy through different mechanisms: first of all it is able to induce the 
expression of proteins related to the ubiquitin- proteasome systems, as MAFbx 
(also known as Atrogin1) or MuRF1 (=muscle ring finger protein). Secondly, the 
expression of inflammatory molecules such as pro-inflammatory cytokines, 
chemokines, cell adhesion molecules and tissue degrading enzymes are 
regulated by NF-kB (Kumar et al., 2004).  
NF-kB belongs to a family of eukaryotic transcription factors, the Rel family. It 
is localized in the cytoplasma. In an inactive state, the NF-kB dimere binds to the 
NF-kB-inhibitors (IkBs). Activation occurs over degradation of IkB, so that the free 
NF-kB is able to enter the nucleus (Fig. 2-9).  
NF-kB may also be a potential actor in muscle development and 
differentiation. It is suggested that it plays an essential role in keeping the 
myoblasts in a proliferating state by stimulating cyclin D1 accumulation and cell 
cycle progression (Guttridge et al., 1999).  
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Figure 2-11: Activation of Nf-kB by inducing signals 
(SanDiego_State_University, 2005) 
 
2.3.2 Influence of TNF-α and IL-6 on skeletal muscle 
metabolism 
 
2.3.2.1 TNF-α  
 
The proinflammatory cytokine tumor necrosis factor (TNF)-α plays an essential 
role in pathological and age-related skeletal muscle atrophy. Skeletal muscle 
cells are able to respond to TNF-α over the two TNF-α receptor isoforms (TNFR1 
and TNFR2) which are both expressed in C2C12 myotubes. In sarcopenia, 
systemic inflammation strongly contributes to muscle atrophy. Particularly TNF-α 
negatively regulates the regeneration capacity over inducing apoptosis of satellite 
cells in the elderly. The effect of TNF-α seems to be threshold and time 
dependent (Degens, 2011). However, not only age-related muscle loss, but also 
muscle wasting, accompanying a lot of disease, is also partly influenced by acute 
and / or chronic inflammation. COPD patients suffering from muscle wasting and 
with no weight increase after nutritional support, were proven to posses high 
circulating levels of TNF-α (Rabinovich and Vilaro, 2011).  
A broad spectrum of literature describes a TNF-α dependent up-regulation of 
atrogin (MAFbx) mRNA in vitro and in vivo. It was shown that this inflammation 
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induced increase of the expression of protein degrading genes, occurs mainly 
over the activation of Foxo4 expression and do not effect Foxo1/3 mRNA levels 
(Moylan et al., 2008) (Fig. 2-12).  
 
 
Figure 2-12: Increase of protein degrading genes by TNF-α (Moylan et al., 2008)  
 
On the other hand, TNF-α was shown to down-regulate PGC-1 (see 2.2.3.1) 
and enhance this way the expression of its alpha target genes atrogin-1 and 
MuRF1 (Tang et al., 2010). This correlates with the finding that PPAR-γ activation 
inhibits inflammation induced NF-kB activity in skeletal muscle (Remels et al., 
2009). In addition, in cachectic COPD patients lower levels of PPAR-γ were 
measured (Rabinovich and Vilaro, 2011).  
TNF-α is not only a key factor in degradation and metabolic pathways, it also 
effects muscle cell differentiation over inhibition of the expression of genes 
involved in myogenic differentiation, as cyclin-dependent kinase inhibitor 1A, p21, 
marker genes as MyoD and others (Chandran et al., 2007).  
TNF-α seems to act mainly over the NF-kB pathway. Although it was proven 
that NF-kB is activated by TNF-α in myotubes, there might exist additional 
signalling for the decreasing effect of TNF-α on IGF1 because no direct influence 
of NF-kB activation on the IGF1 expression level could be measured (Fernandez-
Celemin et al., 2002). The detailed molecular mechanisms between TNF-α 
expression, the expression of muscle markers and growth-related genes and 
muscle wasting therefore remain to be discovered. 
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2.3.2.2 IL-6  
 
IL-6 is a proinflammatory cytokine and involved in acute-phase response in 
case of infection or injury. In skeletal muscle studies it is often mentioned in 
connection with muscle atrophy. It is associated with protein breakdown, 
decreased physical decline and muscle wasting. It was already shown that its 
expression level, especially the level of plasma IL-6, increases with age and 
therefore it is a potential candidate for increasing sarcopenia (Roubenoff, 2003).  
Besides, this cytokine is also upregulated after training as well as after muscle 
damage. IL-6 mRNA expression was shown to be up regulated immediately after 
exercise 10 to 20-fold (Keller et al., 2001).  
Another interesting finding describes that an overexpression of IL-6 in 
transgenic mice leads to muscle atrophy and to an increased level of cathepsins. 
This suggests a role for IL-6 in the activation of the protein degradation 
machinery (Tsujinaka et al., 1995).  
IL-6 expression also seems to be connected to growth factor expression. 
There are more and more evidences that IL-6 and IGF1 levels influence one 
another. High IL-6 was shown to down regulate IGF1 in a broad spectrum of 
literature, and on the other hand it was suggested that a low IGF1 level may 
stimulate IL-6 expression (Sesmilo et al., 2001).  
 
2.3.2.3 Other cytokines 
 
A TNF-α mediated significant up-regulation of different cytokine levels in 
C2C12 skeletal muscles including IFN-γ, IL-6 and the anti-inflammatory cytokines 
IL-9 and IL-10. (Alvarez et al., 2002).  
The modulation in their expression levels in the context of muscle mass 
maintenance let them appear as interesting research targets beside TNF-α and 
IL-6. Proinflammatory cytokines as IL-1β or interferon (IFN)-γ on the one hand 
and anti-inflammatory cytokines as IL-10 on the other hand, may both be 
involved in the crosstalk of skeletal muscle tissue with the environment.  
Like TNF-α, IL-1β also activates the NFkB pathway, but in contrast to TNF-α, 
IGF1 expression seems to be not affected. It was suggested that IL-1β as well as 
IL-1α act via an AKT / Foxo-independent mechanism. They mediate the 
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activation of p38 MAPK, stimulate NF-kB signaling, increase the expression of 
atrogin1 / MAFbx and MuRF1 and reduce the myofibrillar protein content in 
differentiated myotubes (Li et al., 2009).  
 
2.4 miRNAs 
 
2.4.1 Fine tuning of gene expression 
 
miRNAs were discovered recently and are a class of short noncoding 18-22 nt 
long RNA molecules involved in the posttranscriptional regulation of gene 
expression. They are building an additional step of regulation after e.g. 
alternative splicing.  
miRNA mediated gene expression can be found in human, animal and even 
plant genes. It occurs in about 30% of all human genes (Ambros, 2004). The 
exact number of miRNAs is not known but up to date more than 500 human 
miRNA genes have been observed, many of them are evolutionarily conserved.  
 
The interest in miRNAs is growing, as it is known that they play a role not only 
during differentiation but also in cell proliferation, apoptosis tumorigenesis and 
several diseases.  
 
2.4.2 Processing and acting of miRNAs 
 
miRNAs belong to the so called ncRNA (non coding RNA), a part of the RNA 
not coding for proteins. They are transcribed in the nucleus where the primary 
miRNA (pri-miRNA) transcript is encoded in the DNA. The further procession of 
the pri-miRNA is mediated by an enzyme called Drosha which catalyses the 
transport from the nucleus into the cytoplasm (Fig. 2-13).  
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Figure 2-13: Processing and acting of miRNAs (Mack, 2007) 
 
The mature miRNAs become part of the RNA-induced scilencing complex 
(RISC) and negatively regulate gene expression over repressing of protein 
synthesis by blocking translation or causing transcript degradation (Mack, 2007).  
MiRNAs act through complementary base-pairing between the miRNA and the 
3’untranslated region (UTR) of the targeted mRNA (Pillai et al., 2004).  
 
2.4.3 Muscle specific miRNAs 
 
Interestingly, many miRNAs are expressed in a tissue-specific manner, 
suggesting they may play important roles in the regulation of tissue-specific 
genes (Wang, 2006). A miRNAs is called specific if it is expressed only in a 
specific tissue or if its expression level in this tissue is significantly above their 
expression level in other tissues. Recently, it has been discovered that miRNAs 
are also involved in ‘fine-tuning’ the expression of transcription factors and 
signalling mediators important for muscle biology, including the regulation of 
proliferation and the differentiation during myogenesis (Callis et al., 2008). Beside 
these developmentally important processes miRNA influence has been observed 
during muscle diseases such as cardiac hypertrophy or muscular dystrophy.  
miRNA-1, miRNA-206 and miRNA-133a/b were discovered to be specific for 
muscle tissue (McCarthy and Esser, 2007). Whereas miRNA-1 and miRNA-133 
can be found in cardiac and skeletal muscle, miRNA-206 is expressed only in 
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skeletal muscle. MiRNA-1 and miRNA-133 are situated on the same gene locus 
and are therefore transcribed together. In skeletal muscle there expression 
seems to be controlled by MyoD. Interestingly, although the two miRNAs are 
located on the same gene locus miR-1 enhances myogenesis while miRNA-133 
represses it (Chen et al., 2006), (Zhao et al., 2005). As recently discovered, 
miRNA-206 expression causes down regulation of cyclin D1 and phospho-
retinobasma protein and up-regulation of p21 and myogenin (Taulli et al., 2009).  
Other miRNAs found to be expressed in muscle tissue and predicted to play 
important roles in skeletal muscle metabolism are miRNA-499, miRNA-208b and 
miRNA-23a. For miRNA-499 and miRNA-208b a possible role in regulating the 
myostatin gene was described (Drummond et al). For miRNA-23a they indicated 
to act over its predicted targed MEF2C, which it also known to promote a slower 
muscle phenotype. Also miRNA-499, miRNA-208 and miRNA-208b (encoded by 
the intron of Myh7b, alphaMHC and betaMHC, respectively) were proven to be 
involved in fibre type twitch promoting the slow myofibre gene programs 
(McCarthy et al., 2009) (Fig. 2-14).  
   
 
Figure 2-14: miRNA-499 / miRNA-208 mediated regulation of gene expression 
(McCarthy et al., 2009) 
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Sox6, Pur-beta and Thrap1 were proven by the authors mentioned above to 
be important target-genes of miRNA-499 as well as of miRNA-208 and their up- 
regulation during muscle atrophy represses the beta-MHC gene expression and 
by this way down-regulates the slow-twitch MHC isoform expression.  
 
2.4.4 Immuno-related miRNA-155 
 
As the specialized tissues in the body, also the immune system possesses its 
translational regulators. It was proven that some miRNAs react specifically on 
inflammatory stimuli or in association with changed immunological conditions. 
One of the miRNAs related to the immune system is miRNA-155. It was reported 
that miRNA-155 plays a role in the innate immune response as it is up-regulated 
in response to LPS (Tili et al., 2007).  
Inflammatory cytokines, as TNF-α, IL-1 or IFN-γ were shown to increase 
miRNA-155 expression via activation of the JAK/STAT signalling pathway (Kutty 
et al., 2011). As skeletal muscle atrophy is accompanied by inflammatory 
conditions and due to the fact that down-regulation of IGF-1 after TNF-a 
treatment was proven to be JNK-dependent (Frost and Lang, 2007), there might 
be also a role for the immune-related miRNA-155 in connection with muscle 
wasting.  
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3 METHODS 
 
3.1 Cell culture 
 
3.1.1 Specifities of the cell line 
 
To mimic common muscle tissue, we used C2C12 cells, which is a murine 
myoblast cell line (German collection of Microorganisms and Cell Cultures DSMZ, 
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Braunschweig, Germany). These cells grow as an adherent monolayer with a 
doubling rate of approximately 20 hours in optimum proliferating conditions.  
C2C12 cells are mesenchymal progenitor cells with a stem cell like character 
which are often used for experiments in muscle biology due to their specifity to 
differentiate rapidly under changed culture conditions. The differentiation process 
lasts for 3-4 days where the myoblasts stop proliferating, they lose their stem cell 
like character and start to fuse to build the long multinucleated myotubes 
(protocol C2C12 cells, DSMZ).  
 
3.1.2 Growing conditions 
 
For normal proliferation, the cells were cultivated in growth medium (GM).  
This medium consisted of mixture of Dulbecco's Modified Eagle Medium (D-
MEM) (4500 mg/L D-Glucose, Sodium Pyruvate, without L-Glutamine (Gibco, 
Paisley, Scotland) with 2 mM Glutamine (Gibco, Paisley, Scotland) and 10% fetal 
calf serum (FCS; Linaris, Wertheim-Bettingen, Germany). A 0.22 µm filter 
cartridge (SteriCup®- GP Express Plus Filter Unit; Millipore GmbH, Billerica, MA) 
was used to filter the complete medium.  
In this medium the cells were grown to sub confluence, as tight confluent 
layers of cells would lead to a stress situation, abnormal growing and 
uncontrolled differentiation. The cells were incubated under standard conditions 
(37°C, 5% CO 2 and 95% humidity) in a CO2 incubator (MCO-20AIC CO2 Cell 
Culture Incubator with SafeCell™ UV; Sanyo E&E Europe BV Medical Division, 
Etten Leur, Netherlands) and the medium had to be changed every third day.  
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When the cells reached the right density (70% to 80% confluence), they were 
washed with PBS-/- (Gibco, Paisley, Scotland) and differentiation was induced 
using differentiation medium (DM) consisting of D-MEM (4500 mg/L D-Glucose, 
Sodium Pyruvate, Gibco, Paisley, Scotland) supplemented with 2 mM Glutamine 
and 2% Horse serum (Gibco, Paisley, Scotland). For full differentiation, cells were 
incubated in DM under standard conditions (see above) for four days. The 
medium was changed after two days.  
The pictures were taken under an inverse microscope with a digital camera 
with 10 fold magnification.  
 
  
Figure 3-1: First picture: C2C12 myoblasts grown in growth media (proliferating 
cells). Second picture: C2C12 myotubes after serum deprivation (differentiated 
cells) 
 
3.1.3 Subculturing 
 
At a confluence of maximum 80%, cells were washed with PBS -/- and 
Trypsin/EDTA was used to detach the cells. This Trypsin/EDTA incubation lasted 
for 2 minutes and was stopped afterwards with GM. Flasks with pre-warmed GM 
were prepared and the cells were transferred directly with the correct volume of 
suspension to achieve the desired dilution (1:200, 1:100, 1:50 or 1:25).  
If the cell number was determined via cell counting, the entire suspension was 
centrifuged (1,300xg, room temperature, 6minutes). The supernatant was 
discarded and the sample for counting was taken from the pellet resuspended in 
1ml GM.   
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3.1.4 Cell counting 
 
A haemocytometer of the Bürker-Türk type was used (Hecht-Assistant, 
Sondheim, Germany) to count the cells. The counting sample (10µl of cell 
suspension in GM) was diluted 1:2 with 0.4 % trypan blue (Sigma- Aldrich 
Handels GmbH, Vienna, Austria). This treatment helped to determine the number 
of living cells and the number of dead cells. The dead ones appeared blue 
coloured under the microscope in contrast to the colourless living ones. Counting 
took place under a light microscope (Olympus CK2, Olympus, Tokyo, Japan).  
The grid of this type of haemocytometer was divided into 9 big squares. Each 
of these was subdivided into 16 smaller squares with an area of 0.04 mm2 each. 
The depth was fixed to 0.1 mm.  
Five small squares had to be counted.  
  
    
 
Figure 3-2: Bürker-Türk counting chamber. The picture illustrates the five 
squares counted (LO-Laboroptik, 1999) 
 
The final cell number (x 105) was determined using the following formula: 
 
sqaresbigcountedofNumber
cellscounted
mlcellsofNumber 1.0/ ⋅=
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3.1.5 Storage 
 
Subculturing cannot be carried on endlessly. It depends on the life span of the 
cells and their reaction on toxic components like Trypsin as well as to the stress 
they experience during treatment. When using the cells more than a certain 
number of passages, they showed a reduced growing rate and a higher 
percentage of dead cells. To avoid faults and to get statistically more exact 
results, cells were cultivated up to a maximum passage of 14.  
To store C2C12 cells over a longer period of time, they were frozen in liquid 
nitrogen. Therefore cells were grown in GM. When they reached approximately 
the desired number, they were washed 2 times with PBS-/-, detached with 1x 
Trypsin / EDTA (10x stock solution, Invitrogen, Carlsbad, CA), resuspended in 
GM, centrifuged (1,300xg, room temperature, 6min) and the supernatant was 
discarded. Freezing medium (80% GM + 20% FCS) was added to suspend the 
cells. After counting on a haemocytometer, cells were diluted to 3 x 106 cells / ml 
with freezing medium. 1ml aliquots were added to cryo vials and then cooled on 
ice for 5 minutes.  
100 µl DMSO (Sigma-Aldrich Handels GmbH, Vienna, Austria) per vial was 
added. The cells were first frozen at -80°C for 24 hours before they were finally 
transferred to liquid nitrogen for long term storage. 
 
For thawing the cells, the cryo vial with the cell suspension was quickly 
delivered into a water bath (37°C, 2min). After tha wing, the vial was cleaned with 
70% ethanol and then transferred into a cell culture flask (75 cm2, Corning 
Costar, Bodenheim, Germany) with 14 ml pre-warmed GM. Incubation was 
carried out at standard conditions followed by the subculturing process.  
 
3.1.6 Differentiation and stimulation with LPS / TNF-α / 
IL-6 
 
For differentiation, C2C12 cells were seeded in 6 well plates (Corning Costar, 
Bodenheim, Germany) at a density of 0.05 x 105 cells / cm2. After 3 days of 
standard incubation in GM where cells were allowed to settle down, the medium 
was switched to DM. Differentiation lasted for 4 days and medium switch to fresh 
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DM took place after the second day. Samples were taken directly before the 
medium switch and after 4 days of differentiation.  
For time kinetics C2C12 cells were seeded in 6 well plates (Corning Costar, 
Bodenheim, Germany) at a density of 0.05 x 105 cells / cm2. After 3 days of 
standard incubation in GM, the medium was switched to DM (day0). 
Differentiation lasted for 4 days and medium switch to fresh DM took place after 
the second and after the fourth day (day4). Day 4 was the starting point for LPS / 
TNF-α and IL-6 stimulation. For time kinetics concentrations of 1µg / ml LPS 
(E.coli 0111:B4, L4391 Sigma), 10ng / ml TNF-α (mouse recombinant ex. in 
E.coli, T7539, Sigma) and 10ng/ml IL-6 (mouse recombinant ex. In E.coli, I9646, 
Sigma) respectively were used. Samples were taken after differentiation (day 4) 
and after 1, 3, 6, 12, 24 and 48 hours of incubation (Fig. 3-3). 
 
Figure 3-3: Time-kinetics overview, 3 days of proliferation followed by 4 days of 
differentiation. Analyzes were performed at 6 different time points during 
incubation 
 
 
A washing step with PBS-/- was performed before cells were harvested using 
650µl Lysis Binding buffer per well (mirVanaTM miRNA Isolation Kit (Ambion Inc., 
Austin, TX). For all time points the supernatant was taken, centrifuged (14,000xg, 
6min, 4°C) and frozen at -80°C for further analyzes .  
 
 
 
 
1h 
3h 6h 12h 
24h 
48h 
Proliferation  Differentiation  Incubation 
Switch to DM 
(d0) 
LPS / TNF-α /IL6 
stimulation (d4) 
Seeding  
(0.05  x 10
5
 cells/cm²) 
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3.2 Gene expression analyzes 
 
3.2.1 RNA and miRNA isolation 
 
For isolation of total RNA, including miRNAs, the mirVANA miRNA isolation 
kit (Ambion, Austin, TX) was used, which allows simultaneous RNA and miRNA 
isolation. The frozen samples were thawed on ice, vortexed and 550µl of each 
was transferred into new sample tubes to ensure equal starting volumes for all 
samples. Then the isolation procedure was performed according to the 
manufacturer’s instructions.   
Fifty five µl of miRNA homogenate additive (1/10 of the volume) was added to 
each sample, followed by a vortexing step. After 10min incubation on ice, 400µl 
Acid-Phenol:Chloroform solution was added and samples were mixed by intense 
vortexing. Centrifugation (5 min., 14,000xg) was used to separate the liquid into a 
lower organic and an upper aqueous phase which contains the RNA. Four 
hundred fifty µl of this upper phase was transferred into a fresh sample tube and 
mixed with 563µl of absolute ethanol (1.25 x volume) through vortexing. To 
isolate total RNA, the mixture was transferred into a filter cartridge and 
centrifuged (20s, 10,000xg, room temperature). As the maximum volume of the 
filter cartridge was 700µl, the flow through was removed and the collection tube 
was used again for centrifugation of the rest of the sample. Afterwards the filter 
was washed 1 time with 700µl miRNA wash solution 1 and 2 times with 500µl 
wash solution 2/3. Centrifugation between these steps was performed at room 
temperature for 15s at 10,000xg. The flow through was removed and the tubes 
were re-used. To dry the filter, it was centrifuged once more after washing (1 
min., 10,000xg). Then the filter cartridge was transferred into a fresh collection 
tube, 30µl 95°C hot distilled water was added and t he RNA was eluted by 
centrifugation (30s, room temperature, 18,000xg). The eluats of all samples were 
aliquoted, (2µl of each sample was taken for photometric quality and quantity 
control) and stored at -80°C.  
Spectrophotometric measurement of absorbances at 230, 260, 280 and 320 
nm was used to determine the amount of total RNA. The absorbance at 260nm 
shows the concentration of the RNA. This detection method also provides 
information about the quality of the isolated RNA, using the 260 / 280 nm and the 
260 / 230 nm ratios. The ratio of 260 and 280 nm of absorbance is the main 
indicator of the quality of the RNA. If this ratio is lower than 1.6, it is a sign that 
 - 44 - 
the sample is contaminated with proteins. The ratio of 260 and 230 nm 
absorbance provides additional information about RNA purity. A higher ratio than 
0.2 indicates a possible contamination with organic solvents, salts or proteins 
(Gallagher, 2001).  
mRNA and miRNA are extracted by the same procedure, but the amount was 
calculated differently. For total RNA, 1 unit at 260nm means 40µg of RNA per ml. 
Therefore the content of RNA was calculated following the formula below: 
 
 
 
In contrast to the total RNA measurement, 1 unit at 260nm for miRNA 
corresponds to only 33µg per ml. Therefore the formula for the determination of 
the miRNA content includes the factor 3,300 instead of 4,000: 
 
 
 
For photometric measurement, 198µl TE buffer pH 8 (preparation see 
Annexes) and 2µl RNA sample were mixed (1:100 dilution) and measured on the 
spectraphotometer using disposable UVetten (Eppendorf, Hamburg, Germany). 
200µl TE buffer were used as a blank.  
 
3.2.2 mRNA  expression analyzes 
 
3.2.2.1 cDNA synthesis 
 
For cDNA synthesis SuperScript III First Strand Synthesis System for RT- 
PCR (Invitrogen, Carlsbad, CA) was used according to the manufacturer’s 
instructions. Three µg of total RNA in a volume of 8µl were reverse transcribed 
using a blend of Oligo(dT) and random hexamers (1:1) as primer. The samples 
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were thawn on ice and diluted to the desired concentration with dH2O. The 
annealing mix consisting of 8 µl RNA sample, 1µl dNTP and 1µl blend was 
prepared for every sample, heated for 5 min. at 65°C and then placed on ice for 1 
min. Ten µl of a mixture of 2µl 10x RT buffer, 4µl MgCl2, 2µl DTT, 1µl RNase 
OUT and 1µl Super Script RT per sample, called synthesis mix, were added to 
each prepared annealing mix. After a short centrifugation the samples are 
transferred to a Biometra thermocycler (Biometra, Göttingen, Germany). Cycling 
conditions for reverse transcription were chosen according to the manufacturer’s 
instructions  
TIME [min] °C 
25 10 
50 50 
5 85 
∞ 4 
 
After spinning down, 1 µl of RNase H was added to each sample and 
digestion of the RNA template occurred for 20min. at 37°C. Samples were stored 
at -80°C.  
 
3.2.2.2 Real-time qPCR 
 
The influence of the inflammatory stimuli used in this study on muscle cell 
development is measured by analysing the mRNA expression levels of the 
myogenic marker genes MyoD and Myogenin and the insulin-like growth factor 1 
splicing variants IGF1-Ea, IGF1-Eb and MGF. The mRNA expression levels of 
the chosen parameters in the samples were measured using the real-time PCR 
system.  
For the analyzes performed in this study, the Taqman PCR was used, for this 
is a well-established and reliable method in our laboratory. A 7500 Real Time 
PCR System (Applied Biosystems, Foster City, CA) was taken for 
measurements.  
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The Taqman system uses fluorogenic-labeled probes which use the 5´ 
nuclease activity of the Taq DNA polymerase, therefore it is also called 5-prime 
nuclease assay. One of the benefits of the TaqMan system is its increased 
specificity for a certain sequence. This is gained over a probe, an oligonucleotide 
able to anneal to the template between forward and reverse primer. The probe is 
also necessary for detection, as it includes beside the oligonucleotide also the 
reporter and quencher dye. The reporter dyes can be excited by light sources 
and emit fluorescence light. This process is suppressed by the quencher, when it 
is located near the reporter. Therefore there is no emission light present for intact 
annealed probes. The polymerase possesses exonuclease activity and cleaves 
the probe during each extension cycle, separating the quencher from the reporter 
which then starts to emit light (Applied_Biosystems, 2008) (Fig. 3-4).  
 
Figure 3-4: TaqMan PCR schematic (Applied_Biosystems, 2008) 
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Measuring the fluorescence, the amount of target gene RNA is determined. 
Data analyzes were performed with the 7500 System SDS v1.4 software (Applied 
Biosystems. Foster City, CA). For analyzes a threshold line has to be set. This 
line marks the cycle in the exponential phase of amplification, where the 
measured fluorescence exceeds background fluorescence (Ct = cycle threshold). 
The amount of target DNA in the sample determines when fluorescence reaches 
the Ct.  
 
3.2.2.3  MyoD / Myogenin mRNA expression 
 
The cDNA of the samples was diluted to 6,125ng / µl with ddH2O. For analysis 
of MyoD and myogenin TaqMan Gene Expression Assays 20x primer and MGB 
probe (Applied Biosystems, Foster City, CA) and FAM dye-labeled mix for 
MyoD (Assay ID Mm00440387_m1) or myogenin (Assay ID Mm00446194_m1) 
was used. The housekeeping gene GAPDH (Mouse GAPDH 20x, Pre Developed 
TaqMan Assay Reagents 4352932 E, Applied Biosystems) was used as 
endogenous control, which is described in literature as a reliable control 
according to its equally expression in muscle tissue and C2C12 cell culture 
(Barber et al., 2005).  
The standard was prepared by using pooled samples, which were diluted four 
times in 1:10 steps. The concentration ranges therefore from 250ng to 0.025ng 
RNA / well. Real-time PCRs were performed using PCR plates (96 well Optical 
plate with barcode, Foster City, CA). For one well, 16µl Master Mix, consisting of 
10µl TaqMan Gene Expression Master Mix (Applied Biosystems), 1µl Primer 
and 5µl dH2O were combined with 4µl of diluted sample. Per well, a total of 25ng 
of RNA was used. Analyzes were performed in duplets with dH2O instead of 
sample as a negative control (NTC). Cycling conditions shown below (table 3.1). 
 
Table 3.1: Real-time PCR cycling conditions; A/E = Anneal/Extend 
Melt 
HOLD HOLD 
2 min 10 min 15 sec 1 min
50°C 95°C 95°C 60°C 
Initial steps Each of 45 Cycles 
CYCLE 
Times and Temperatures 
A/E
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3.2.2.4  IGF1-Ea, IGF1-Eb and MGF mRNA expression  
 
For specific amplification of the splicing variants of the IGF1 gene, primers 
suitable for real-time PCR were designed.  
The mRNA sequences of the target genes were gained from DNA data bases 
(NCBI / Celera) and the quality of the mRNA was then proofed according to the 
protocol for Bioinformatic Evaluation of a Sequence for Custom TaqMan Gene 
Expression Assays (Applied Biosystems).  
Primer and probe design was performed using primer express software. IGF1-
Ea, IGF1-Eb and MGF differ in the combination of their exons and therefore 
primers were placed over the various exon borders, which allow a specific 
recognition and therefore amplification of all three genes:  
IGF-1Ea: Exon 5 (forward primer), Exon 5/6 (probe), Exon 6 (reverse primer) 
IGF-1Eb: Exon 4/5 (forward primer), Exon 5 (probe), Exon 5 small (reverse 
primer) 
MGF: Exon 5/6 (forward primer), Exon 6 (probe), Exon 6 (reverse primer) 
 
The different splicing variants of the mus musculus IGF1 gene:  
 
 
 
 
 
  
             
 
 
IGF Gene 
IGF1-Ea 
IGF1-Eb 
MGF 
 
Exon 5 Exon 6 Exon 4 Exon 3 
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Primer / Probe sequences of the three target genes (table 3-2):  
 
mmuIGF1-Ea forward 5’-CTTCCGGAGCTGTGATCTG-3’ 
 reverse 5’-TCTTGTTTCCTGCACTTCCTC-3’ 
 probe 5’-TGACATGCCCAAGACTCAGAAGGAAGT-3’ 
mmuIGF1-Eb forward 5’-TCAGAAGTCCCCGTCCCTAT-3’ 
 reverse 5’-AGTTGCCTCCGTTACCTCCT-3’ 
 probe 5’-AGAAGGAAAGGTGAGCCAAAGACACA-3’ 
mmuMGF forward 5’-GCAAAGGAGAAGGAAAGGAAGTA-3’ 
 reverse 5’-TGTTTTGCAGGTTGCTCAAG-3’ 
 probe 5’-6FAM-GGAGCCTCCCACGGAGCAGA-TAMRA-3’ 
 
Table 3-2: Primer and probe sequences;  = Exon border 
 
As for myogenin and MyoD PCRs, the cDNA of the samples was diluted to 
25ng / well with ddH2O. The pre-tested primers for IGF1-Ea, IGF1-Eb and MGF 
were used in a concentration of 300nmol, the probe in a concentration of 
250nmol, all diluted in dH2O. As before, GAPDH was used as an endogenous 
control and dH2O as a negative control.  For standard, the same sample pool 
and the same concentrations were taken as for MyoD / Myogenin.  
 
Real-time PCRs with designed primers were performed using 16µl Master Mix 
per well, consisting of 10µl TaqMan Gene Expression Master Mix (Applied 
Biosystems), 2µl of forward and 2µl of reverse Primer, 2µl probe and 5µl of 
dH2O. This was combined with 4µl of diluted sample.  
 
3.2.3  miRNA expression analyzes 
 
The transcription and amplification through real-time PCR of miRNAs slightly 
differs from that of mRNAs. A main problem when analyzing miRNAs is their 
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shortness. The normally used mRNA transcription procedure with a random 
primed reverse transcription step is not possible for a length of 18-22 nucleotides. 
Therefore a primer containing a target-specific stem loop structure was designed. 
Beside the so gained specificity for mature miRNAs, these target-specific RT 
primers fulfil another function: the resulting product of the transcription step is a 
combination of the mature miRNA and the primer, longer as the originally mature 
miRNA and therefore a suitable template for RT-PCR.   
  
Figure 3-5: TaqMan® miRNA Assay Mechanism (Ambion, 2010) 
 
These stem-loop primers are better than conventional ones in terms of PCR 
efficiency and specificity and they are not affected by genomic DNA 
contamination (Chen et al., 2005). According to the authors the better specificity 
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and sensitivity could be a result of base stacking, which may improve the thermal 
stability of the primer/RNA duplex. The spatial constraint of the stem-loop 
structure could prevent it from binding to double-strand genomic DNA.  
 
3.2.3.1 cDNA synthesis 
 
For cDNA synthesis, the TaqMan miRNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA) was used, which allows TaqMan RT-PCR 
amplification afterwards. Specific transcription of miRNAs into cDNA was 
performed according to the protocol (TaqMan miRNA Reverse Transcription Kit 
protocol).   
Reverse transcription was performed with the TaqMan miRNA assays 
(Applied Biosystems, Foster City, CA, hsa-miR-206, hsa-miR-1, hsa-miR-133a, 
hsa-miR-133b, has-miR-499, has-miR-208 and hsa-miR-155) and TaqMan 
Gene Expression Master Mix (Applied Biosystems, Foster City, CA). MiRNAs are 
conserved throughout species which allows for our trials the use of human 
primers for murine miRNAs.  
An amount of 10ng RNA / 5µl was reverse transcribed. This calculation is 
based on the miRNA content and assumes a complete transcription of miRNA 
into cDNA. The Master Mix, containing 0,15µl 100mM dNTPs, 1,5µl 10 x reverse 
transcription buffer, 1µl MultiScribe ™ RT, 0,19µl RNase Inhibitor (20 U / µl) and 
4,16µl ddH2O was prepared. After dilution of the miRNA to the right 
concentration, 5µl of the sample was mixed with 3µl primer mix and with 7µl of 
the Master Mix.  
The Reference Panel (mirVana 4388891, Applied Biosystems), which serves 
as a standard for PCR, was diluted in 1:10 steps and each dilution was reverse 
transcribed, using 5µl of standard dilution, 7µl Master Mix and 3µl primer mix.  
A Biometra thermocycler (Biometra, Göttingen, Germany) was used for 
converting miRNA into cDNA (cycling conditions see table 3-3) and samples were 
stored at -80°C.  
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TIME [min] °C 
30 16 
30 42 
5 85 
∞ 4 
Table 3-3: MiRNA specific reverse transcription conditions 
 
3.2.3.2 miRNA expression 
 
For miRNA RT-PCR 96-well PCR plates (optical plate with barcode, Applied 
Biosystems, Foster City, CA) were used. The PCRs were all carried out due to 
the manufacturer’s instructions. A Reference Panel, already diluted in 1:10 steps 
before the reverse transcription, was used as a standard, with the highest 
concentration of 1 fmol and the lowest of 0,0001 fmol. This Reference Panel 
consists of a mix of different miRNAs and allows absolute quantification. ddH2O 
was used as a negative control.  
The samples were analyzed in duplets. For each well 10 µl of TaqMan Gene 
Expression Master Mix (Applied Biosystems, Foster City, CA), 8 µl ddH2O and 1 
µl of miRNA assay (20x, miR-1, -206, -133a, -133b, -155) was used. To this mix 
1 µl of the reverse transcription product was added.    
Cycling conditions are shown below (table 3-4) 
 
 
 
 
 
 
 
 
Table 3-4: miRNA real-time PCR cycling conditions  
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3.2.4 Protein determination 
 
ELISAs were used to determine the concentration of our proteins of interest 
from cell culture supernatants.  
The ELISAs (enzyme-linked immunosorbent assay) is a biochemical 
technique, which is used to recognize a specific antigen in a sample. There are 
several types of ELISAs, as the indirect or the competitive ELISA, which are all 
using the antibody-antigen recognition, but in different combinations.  
The ELISA used here is a sandwich-type ELISA (antibody-antigen-antibody).  
 
 
Figure 3-6: Sandwich ELISA schematic (Biosystemdevelopment, 2006) 
 
A sandwich ELISA is carried out on a solid surface on which capture 
antibodies, with a specific binding site for the antigen, are immobilized. When the 
samples are added, the antigens are able to bind the antibodies while the rest of 
the sample is removed by several washing steps. For labelling, a second 
antibody, which is able to recognize the same antigen, is used. This second 
antibody is coupled to an enzyme. During incubation, this enzyme catalyzes a 
reaction so that its substrate becomes detectable over an observable color 
change or a fluorogenic signal. The measurement of the enzymatic activity 
corresponds to the concentration of the captured antigens. 
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This way the analyzes of the detectable signal determines the presents of the 
antigen of interest and its quantity.  
 
3.2.4.1 IGF-1 
 
To measure the concentration of IGF-1 protein in the cell culture supernatants, 
a mouse IGF-1 Immunoassay (Quantikine, R&D Systems, Minneapolis, US) was 
used. This assay is a solid phase ELISA, containing recombinant mouse IGF-1 
and antibodies against it. With this kit it is possible to measure the concentration 
of natural mouse IGF-1.  
Supernatants were taken 4 days after differentiation and 1, 3, 6, 12, 24 and 48 
hours after stimulation with TNF-α, LPS or IL-6. Before freezing, they were 
centrifuged (14,000xg, 10min, 4°C) to eliminate eve ntually disturbing 
components. After centrifugation, supernatants were split up and transferred into 
sterile sample tubes. Samples were stored at -80°C until further analyzes.  
The assay was used according to the manufacturer’s instructions. Samples 
were thawn at room temperature, centrifuged (10,000xg, 3min) and diluted 1:3 
with Calibrator Diluent RD5-38.  
All reagents were prepared due to the kit protocol. Recombinant mouse IGF-1 
was prepared at a concentration of 2000pg / ml and then diluted in 1:2 steps 
down to 31,2pg / ml with Calibrator Diluent RD5-38, was used as a standard.  
 
Analyzes were performed on a 96well mouse IGF-1 microplate, coated with 
the monoclonal antibody specific for mouse IGF-1. Fifty µl Calibrator Diluent were 
added to each well, followed by 50µl of the diluted sample, standard or control. 
Then the plate was covered and incubated (2h on the shaker, room temperature). 
Thereafter, the solution was discarded and each well was washed five times with 
wash buffer. The liquid was removed completely, and 100µl of mouse IGF-1 
conjugate (mixture of stabilized hydrogen peroxide and the stabilized chromogen 
tetramethylbenzidine) which was used as substrate solution, was added to each 
well followed by 30min of incubation in the dark. After that, the washing step with 
wash buffer was repeated and the enzymatic substrate reaction was stopped by 
adding 100µl of stop solution to each well.  
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The optical density was measured on a ELISA reader (Victor 3, Perkin Elmer) 
at 450nm with a correction wavelength at 555nm.  
 
3.2.4.2 TNF-α  
 
The concentration of TNF-α in the cell culture supernatants was measured 
using a mouse TNF-α Immunoassay (Quantikine, R&D Systems, Minneapolis, 
US). This assay uses the same principles as the IGF-1 ELISA (see above).  
Supernatants were taken 4 days after differentiation and 1, 3, 6, 12, 24 and 48 
hours after stimulation with TNF-α, LPS or IL-6. Before freezing, they were 
centrifuged (14,000xg, 10min, 4°C) to eliminate eve ntually disturbing 
components. After centrifugation, supernatants were aliquoted and transferred 
into sterile sample tubes. Samples were stored at -80°C until further analyzes. 
The assay was used according to the manufacturer’s instructions.  
Supernatants were thawn at room temperature and centrifuged (10,000xg; 
3min). The TNF- α ones had to be diluted 1:10 with Calibrator Diluent RD5-38 
due to their original high concentration of TNF-α. All other samples were used 
directly without dilution. Recombinant mouse TNF-α was prepared at a 
concentration of 1,500pg / ml and further diluted in 1:2 steps down to 23.4pg / ml. 
Calibrator Diluent RD5-38 was used as a standard.  
Analyzes were carried out as mentioned above (see chapter 3.2.4.1).  
 
3.2.4.3 IL-6  
 
The concentration of IL-6 in the cell culture supernatants was measured by 
using a mouse IL-6 Immunoassay (Quantikine, R&D Systems, Minneapolis, US). 
Supernatants were taken 4 days after differentiation and 12, 24 and 48 hours 
after stimulation with TNF-α, LPS or IL-6. For protocol, sample preparation and 
analyzes see above (Chapter 3.2.4.2).  
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3.3 Statistical Analysis 
 
Statistical evaluation was performed using SPSS software (SPSS software 
package for Windows, Version 8.0.0, Chicago, IL). Group comparisons during 
differentiation test were performed using independent t-tests. Levene tests were 
used to test for equality of variances. For time kinetic measurements a repeated 
measured ANOVA was performed to calculate time (0, 1, 3, 6, 12, 24, 48h), 
group (control, LPS, TNFα, IL-6) and time x group interactions. Post hoc Dunnett 
T-Tests were performed to describe differences between groups and/or time 
points.  
Data are shown as mean ± SD (mean values ± standard deviation) and a p 
value < 0.05 was considered as being statistically significant.  
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4 RESULTS 
4.1 Myoblast differentiation 
 
 In all trials cells were seeded at a density of 0.05 x 105 cells / cm² and allowed 
to adhere for three days before changing either to new GM or starting 
differentiation by adding DM instead of GM. Cells were counted on day 0, day 1, 
day 2, day 3 and day 4 using Bürker-Türk haemocytometer in order to determine 
the proliferative capacity of the cells during the different growth conditions. Data 
are shown as mean (normalized to day 0) ± SD (* p<0.05 and *** p<0.001 vs. day 
0; Fig. 4-1). 
 
Figure 4-1: Cell number of C2C12 cells grown in GM and cells grown in DM  
 
Statistical analysis of cell number revealed a significant time effect (p=0.000), 
time x group interaction (p=0.000) and group effect (p=0.000).   
While the cells in GM proliferated, the differentiating cells nearly stopped 
growing and fused to form myotubes. The number of cells grown in GM 
increased significantly on day 3 and day 4 to the 21.2-fold (p<0.001) and the 
25.1- fold (p<0.001) level, respectively, when compared to the number of cells at 
day 0. From day 0 to day 4 the number of cells grown in DM increased 5.3-fold 
(p<0.05) but to a lesser extent then cells grown in GM. 
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4.1.1 Myogenic marker gene expression 
 
The expression of the myogenic marker genes MyoD and Myogenin was 
analyzed in order to determine the differentiation state of C2C12 cells. While 
MyoD should be expressed already in myoblasts, myogenin should be induced 
during differentiation of myoblasts to myotubes. 
After cells were settled, GM was switched to DM. Incubation lasted for 4 days 
in differentiation media. For the myogenic markers MyoD and Myogenin 
measurements took place on day 0, before adding the DM (myoblasts), and after 
4 days of differentiation (myotubes). For relative quantification the house keeping 
gene GAPDH was used and mRNA was analyzed via real-time PCR.  
 
4.1.1.1 MyoD 
 
Figure 4-2: Expression of MyoD / GAPDH.   
 
Data are shown as mean ± SD, n=3. Expression levels of MyoD did not 
change during differentiation (Fig. 4-2).  
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4.1.1.2 Myogenin 
 
 
Figure 4-3: Expression of Myogenin / GAPDH.  
 
Data are shown as mean ± SD (* p<0.05, n=3). Myogenin levels increased 
7.1-fold during differentiation from myoblasts to myotubes (Fig. 4-3). 
 
4.1.2 IGF-1 splicing variants 
 
IGF-1Ea, MGF and IGF-1Eb comprise important growth factors for muscle 
cells and are therefore interesting parameters in the context of muscle atrophy.  
As for the myogenic markers, IGF-1 splicing variant mRNA expression was 
measured on day 0, before adding the DM, and after 4 days of incubation. For 
relative quantification the house keeping gene GAPDH was used and mRNA was 
analyzed via real-time PCR.  
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Figure 4-4: Expression of IGF-1Ea / GAPDH.  
 
Data are shown as mean ± SD (* p<0.05, n=3) IGF-1Ea mRNA was up-
regulated 36.1-fold during differentiation (Fig. 4-4). 
 
  
Figure 4-5: Expression of IGF-1Eb / GAPDH. 
 Data are shown as mean ± SD (n=3). In contrast to IGF-1Ea, IGF-1Eb 
expression did not significantly change during differentiation (Fig. 4-5). 
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Figure 4-6: Expression of MGF / GAPDH. 
 
Data are shown as mean ± SD (* p<0.05, n=3) MGF mRNA was increased 
30.9-fold during differentiation (Fig. 4-6). 
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4.1.3 miRNA expression 
 
In order to determine the influence of differentiation on muscle-specific 
miRNAs, their expression level were analyzed on day 0, before adding the 
differentiation media, and after 4 days of incubation. Additionally, an immuno-
related miRNA (miRNA-155) was included as control. miRNAs were measured by 
absolute quantification using a reference panel with known equimolar 
concentrations of different miRNAs as a standard. miRNAs were analyzed via mi-
RNA-specific real time PCR . 
4.1.3.1 Muscle specific miRNAs 
 
The expression levels of miRNA-1, -206, -133a, -133b and -499 were 
measured, as these miRNAs comprise important regulatory factors for muscle 
cell differentiation.  
  
 
Figure 4-7: Expression of miRNA-1.  
 
 Fig. 4-7 shows the absolute amount of miRNA in the concentration of pmol / 
ng. Data are shown as mean ± SD (* p<0.05, n=3). The expression level of 
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miRNA-1 increased 464-fold in comparison to undifferentiated myoblasts. 
Interestingly, the initial values of miRNA-1 were very low. 
 
 
Figure 4-8: Expression of miRNA-206.  
 
The absolute amount of miRNA-206 in the concentration of pmol / ng is shown 
in Fig. 4-8. Data are shown as mean ± SD (*** p<0.001, n=3). For miRNA-206 a 
significant increase after incubation with DM was detected. The expression level 
of miRNA-206 was enhanced to 14.3-fold in comparison to the initial level before 
differentiation. 
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Figure 4-9: Expression of miRNA-133a.  
 
 Fig. 4-9 depicts the absolute amount of miRNA-133a in the concentration of 
pmol / ng. Data are shown as mean ± SD (** p<0.01, n=3). miRNA-133 increased 
461-fold during differentiation. 
 
 
Figure 4-10: Expression of miRNA-133b.  
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Fig. 4-10 shows the absolute amount of miRNA-133b in the concentration of 
pmol / ng. Data are shown as mean ± SD (* p<0.5, n=3). We detected a 16.5-fold 
increase of miRNA-133b during differentiation. 
 
 
Figure 4-11: Expression of miRNA-499.  
 
 The absolute amount of miRNA-499 in the concentration of pmol / ng is 
shown in Fig. 4-11. Data are shown as mean ± SD (n=3). We detected a 
tendency for upregulation for miRNA-499 during differentiation, however, due to 
the high standard deviation and the small sample size, the change in expression 
level was not significant. 
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4.1.3.2 Immune-related miRNA 
 
  As it was proven that miRNA-155 is up-regulated in response to LPS (Tili et 
al., 2007) it may also be involved in inflammation-induced muscle changes which 
is the focus of the second set of our experiments. However, miRNA-155 should 
not change during differentiation. 
 
 
Figure 4-12: Expression of miRNA-155.  
 
 Fig. 4-12 shows the absolute amount of miRNA-155 in the concentration of 
pmol / ng. Data are shown as mean ± SD (n=3). As expected miRNA-155 levels 
did not change due to differentiation. 
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4.2 Myotube stimulation with inflammatory 
substances 
 
Cells were seeded at a density of 0.05 x 105 cells / cm². They were allowed to 
settle for three days and then differentiated through serum deprivation. After four 
days in DM, the fully differentiated cells were stimulated either with 
Lipopolysaccharid (LPS), TNF-α or IL-6. PBS -/- was used as a vehicle as 
described in chapter 3.1.6.  
Time kinetics were performed and analyzes took place 1h, 3h, 6h, 12h, 24h 
and 48h after stimulation. Measurements of all parameters were done via real 
time PCR and miRNA-specific PCR, respectively. 
 
4.2.1 Myogenic marker gene expression 
 
4.2.1.1 MyoD  
 
Statistical analysis of MyoD mRNA levels revealed a significant time effect 
(p=0.000) but neither a group effect (p=0.738) nor a time x group interaction 
(p=0.664) (Fig. 4-13).   
MyoD expression was down-regulated significantly after 1h to 70.2 ± 9.3% 
(p<0.05) for the control, to 69.0 ± 7.9% (p<0.01) for IL-6, and to 72.1 ± 6.2% 
(p<0.01) for TNF-α. LPS treatment also seems to down-regulate MyoD at this 
time-point (74.3 ± 12.1%), however the change in expression level was not 
significant (p=0.199).  Thereafter, expression levels of MyoD returned to baseline 
levels in all experimental groups with the exception of treatment with TNF-α 
which resulted in an additional decrease after 12 hours of incubation. At this time 
point TNF-α leads to a drop of MyoD expression to 61.3 ± 6.2 % (p<0.001) 
staying at a low level until the end of the kinetic at 48h.   
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Figure 4-13: MyoD mRNA expression  
 
Fig. 4-13 shows the MyoD mRNA expression after stimulation with vehicle 
(blue), 10ng/ml  IL-6 (yellow), 1µg/ml LPS (green), and 10ng/ml TNF-α (red) for 
up to 48 hours. The ratios of MyoD/GAPDH normalized to 0h are shown as mean 
± SD (* p<0.05, ** p<0.01 and *** p<0.001 vs. 0h, n=4). 
 
4.2.1.2 Myogenin 
 
 Statistical analysis of myogenin mRNA levels revealed a significant time 
effect (p=0.000). The time x group interaction (p=0.767) and the group effect 
(p=0.506) were not significant (Fig. 4-14).  
Time-kinetics of myogenin mRNA expression showed a general reduction of 
the expression levels of all experimental groups when compared to d4. The 
reduction in myogenin expression reached significance 6h after TNF-α 
stimulation, when it dropped to 65.4 ± 15.3% (p<0.05). The significantly low level 
was kept also after 12h, 24h and 48h when it decreased to 39.2 ± 15.3% 
(p<0.01), 46.0 ± 15.3% (p<0.01) and 43.6 ± 15.3% (p<0.01), respectively. 
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 Interestingly, also the control decreased to 57.3 ± 11.7% (p<0.01) after 12h 
and to 54.3 ± 11.7% (p<0.01) after 24h. However, 48h after the start of the 
stimulation experiment myogenin levels of the control cells tend to normalize.  
Myogenin level did not decrease significantly due to IL-6 or LPS treatment.   
  
 
Figure 4-14: Myogenin mRNA expression  
 
Fig. 4-14 shows the myogenin mRNA expression after stimulation with vehicle 
(blue), 10ng/ml  IL-6 (yellow), 1µg/ml LPS (green), and 10ng/ml TNF-α for up to 
48 hours. The ratios of myogenin/GAPDH normalized to 0h are shown as mean ± 
SD (* p<0.05 and ** p<0.01 vs. 0h, n=4). 
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4.2.2 IGF-1 splicing variants 
 
 Statistical analysis if IGF-1Ea mRNA levels revealed a significant time effect 
(p=0.000) and time x group interaction (p=0.000), whereas the group effect was 
not significant (p=0.236) (Fig. 4-15).  
The reduction of IGF-1Ea mRNA, compared to the control at 0h, could already 
be observed 6h after TNF-α stimulation, when it dropped to 67.1 ± 11.3% 
(p<0.01).  After 12h of TNF-α stimulation the IGF-1Ea expression level decreased 
to 34.3 ± 11.3 % (p<0.001). The expression level remained low at 41.0 ± 11.3% 
(p<0.001) after 24h and at 65.6 ± 11.3% (p<0.01) after 48h of TNF-α stimulation.  
An increase of mRNA expression could be detected for the control as well as 
after stimulation with LPS or IL-6, starting 12h after incubation and reaching a 
significant maximum of 65.0% ±17.0% (p<0.01) after 48h for LPS-incubated cells 
as well as of 72.0 ± 13.9% (p<0.001) for the control.  
IL-6 stimulation did not affect IGF-1Ea expression level. 
 
Figure 4-15: IGF-1Ea mRNA expression 
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Fig. 4-15 shows the IGF-1Ea mRNA expression after stimulation with vehicle 
(blue), 10ng/ml  IL-6 (yellow), 1µg/ml LPS (green), and 10ng/ml TNF-α for up to 
48 hours. The ratios of IGF1Ea/GAPDH normalized to 0h are shown as mean ± 
SD (** p<0.01 and *** p<0.001 vs. 0h, n=4).  
 
Statistical analysis of IGF-1Eb mRNA levels revealed a significant time effect 
(p=0.000) but not a significant time x group interaction (p=0.809) and group effect 
(p=0.236), respectively.  
Fig. 4-16 shows the reduction of IGF-1Eb compared to the control at the time 
point 0h. We could observe a significant down-regulation of IGF-1Eb expression 
to 69.9 ± 10.1% (p<0.05), to 65.4 ± 10.1% (p<0.05) after 6h, to 61.0 ± 10.1% 
(p<0.01) after 12h, and to 62.4 ± 10.1% (p<0.01) after 24h of IL-6 stimulation.   
Neither LPS nor TNF-α incubation had a detectable effect on the IGF-1Eb 
expression level. 
 
 
 
Figure 4-16: IGF-1Eb mRNA expression  
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Fig. 4-16 shows the IGF-1Eb expression after stimulation with vehicle (blue), 
10ng/ml  IL-6 (yellow), 1µg/ml LPS (green), and 10ng/ml TNF-α for up to 48 
hours. The ratios of MyoD/GAPDH normalized to 0h are shown as mean ± SD (* 
p<0.05 and ** p<0.01 vs. 0h, n=4). 
 
 Statistical analysis of MGF mRNA levels revealed a significant time effect 
(p=0.000). The time x group interaction (p=0.662) and the group effect (p=0.397) 
were not significant.  
Compared to the control at the time point 0h, MGF mRNA was down-regulated 
significantly already 6h after TNF-α treatment to 61.7 ± 11.4% (p<0.05) reaching 
a minimum of 32.3 ± 11.4 % (p<0.001) 12h after stimulation. The expression level 
of MGF stayed low at 51.2 ± 11.4% (p<0.01) also for the time point 24h and at 
63.0 ± 11.4% (p<0.05) for the time point 48h.  
LPS stimulation caused a significant decrease of MGF levels to 58.4 ± 12.5% 
(p<0.05) after 12h. However, 48 hours of LPS incubation caused a significant 
increase of 45.0 ± 12.5% (p<0.01) of MGF expression, correlating with a general 
increase of 59.2 ± 14.1% (p<0.001) also for the control. No detectable effect of 
IL-6 stimulation on MGF expression level could be observed. 
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Figure 4-17: MGF mRNA expression  
 
 Fig. 4-17 shows the MGF mRNA expression after stimulation with vehicle 
(blue), 10ng/ml  IL-6 (yellow), 1µg/ml LPS (green), and 10ng/ml TNF-α for up to 
48 hours. The ratios of MGF/GAPDH normalized to 0h are shown as mean ± SD 
(* p<0.05, ** p<0.01 and *** p<0.001 vs. 0h, n=4). 
 
4.2.1 miRNA expression 
 
For miRNA analyzes the differentiated cells were stimulated with either 10 ng / 
ml of TNF-α or with 1 µg / ml of LPS. PBS -/- was used as a vehicle. IL-6 
stimulation was omitted as we did not detect any changes in myogenic markers 
or the IGF-1 system due to stimulation with IL-6. 
Under the influence of the inflammatory stimuli, the miRNA expression level of 
the muscle specific miRNAs -1, -206, -133a, -133b and 499 and of the immuno-
specific miRNA-155 was measured via miRNA-specific PCR as described in 
chapter 3.2.3. MiRNAs were measured over absolute quantification, using a 
reference panel with known equimolar concentrations of different miRNAs as a 
standard.  
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4.2.1.1 Muscle-specific miRNAs 
 
None of the here examined muscle-specific miRNAs showed a significant 
change of the expression level after stimulation with either LPS or TNF-α (see 
Figures 4-18, 4-19, 4-20, 4-21, and 4-22). 
 
 
 
Figure 4-18: miRNA-1 expression  
 
Fig. 4-18 shows miRNA-1 expression after stimulation with vehicle (blue), 
1µg/ml LPS (green), and 10ng/ml TNF-α (yellow) for up to 48 hours. The amount 
of miRNA-1 was measured as absolute quantification with reference panel as a 
standard and is shown here as the x-fold change in relation to 0h. Data are 
expressed as mean ± SD, n=4. 
Statistical analysis of miRNA-1 levels did not reveal any significant time effect 
(p=0.559), group effect (p=0.878) or time x group interaction (p=0.989). 
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Figure 4-19: miRNA-206 expression  
 
Figure 4-19 shows miRNA-206 expression after stimulation with vehicle (blue), 
1µg/ml LPS (green), and 10ng/ml TNF-α (yellow) for up to 48 hours. The amount 
of miRNA-1 was measured as absolute quantification with reference panel as a 
standard and is shown here as the x-fold change in relation to 0h. Data are 
shown as mean ± SD, n=4. 
Statistical analysis of miRNA-206 levels did not show any significant time 
effect (p=0.714), group effect (p=0.235) or time x group interaction (p=0.705). 
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Figure 4-20: miRNA-133a expression  
 
Fig. 4-20 shows the miRNA-133a expression after stimulation with vehicle 
(blue), 1µg/ml LPS (green), and 10ng/ml TNF-α (yellow) for up to 48 hours. The 
amount of miRNA-1 was measured as absolute quantification with reference 
panel as a standard and is shown here as the x-fold change in relation to 0h. 
Data are shown as mean ± SD, n=4. 
Statistical analysis of miRNA-133a levels did not reveal any significant time 
effect (p=0.093), group effect (p=0.665) or time x group interaction (p=0.994). 
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Figure 4-21: miRNA-133b expression  
 
Fig. 4-21 shows miRNA-133b expression after stimulation with vehicle (blue), 
1µg/ml LPS (green), and 10ng/ml TNF-α (yellow) for up to 48 hours. The amount 
of miRNA-1 was measured as absolute quantification with reference panel as a 
standard and is shown here as the x-fold change in relation to 0h. Data are 
shown as mean ± SD, n=4. 
Statistical analysis of miRNA-133b levels revealed a significant time effect (p = 
0.047) whereas the time x group interaction (p=0.956) and the group effect 
(p=0.665) were not significant. 
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Figure 4-22: miRNA-499 expression  
 
Fig. 4-22 shows miRNA-499 expression after stimulation with vehicle (blue), 
1µg/ml LPS (green), and 10ng/ml TNF-α (yellow) for up to 48 hours. The amount 
of miRNA-1 was measured as absolute quantification with reference panel as a 
standard and is shown here as the x-fold change in relation to 0h. Data are 
shown as mean ± SD, n=4. 
Statistical analysis of miRNA-499 levels did not reveal any significant time 
effect (p=0.465), time x group interaction (p=0.298) and group effect (p=0.280). 
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4.2.1.2 Immune-related miRNAs 
 
 
Figure 4-23: miRNA-155 expression  
 
Fig. 4-23 shows miRNA-155 expression after stimulation with vehicle (blue), 
1µg/ml LPS (green), and 10ng/ml TNF-α (yellow) for up to 48 hours. The amount 
of miRNA-1 was measured as absolute quantification with reference panel as a 
standard and is shown here as the x-fold expression in relation to 0h. Data are 
shown as mean ± SD, n=4. 
Statistical analysis of miRNA-155 levels revealed no significant time effect 
(p=0.327), time x group interaction (p=0.738) and group effect (p=0.700). 
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4.3 IGF-1, IL-6, and TNF-α concentration in cell culture 
supernatants 
 
ELISAS were used to determine the content of total IGF1 protein before and 
during stimulation as an additional indicator for possible translational inhibition 
and a comparison to IGF-1 mRNA levels. TNF- α and IL-6 protein was analyzed 
to test the stability of the used stimuli as well as for a suggested induced 
expression of these cytokines after stimulation with inflammatory stimuli.  
 
4.3.1 Determination of IGF-1 
 
The concentration of the IGF-1 protein in the cell culture supernatants was 
analyzed after 0h, 1h, 3h, 6h, 12h, 24h and 48h of incubation with LPS, TNF-α 
and IL-6, respectively via ELISA.  
 
Figure 4-24: IGF-1 protein concentration  
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 Fig. 4-24 shows IGF-1 protein concentration after stimulation with vehicle 
(blue), 1µg/ml LPS (green), 10ng/ml TNF-α (yellow) and 10ng / ml IL-6 (pink) for 
up to 48 hours. IGF concentrations in supernatants are shown as the x-fold 
change in relation to 0h. Data are shown as mean ± SD (* p<0.05, ** p<0.01 and 
*** p<0.001, vs. 0h, n=3). 
Statistical analysis of IGF-1 ELISA revealed a significant time effect (p=0.000) 
and group effect (p=0.000), whereas the time x group interaction was not 
significant (p=0.212). 
Compared to the IGF-1 concentration at 0h the level increased significantly 
2.2-fold after 48h in the control (p<001), 2.8-fold after LPS incubation (p<0.01) 
and 1.4-fold after IL-6 incubation (p<0.05). No significant change of IGF-1 
concentration after TNF-α stimulation could be detected. 
 
4.3.1 Determination of TNF-a  
 
The concentration of the TNF-α protein in the cell culture supernatants was 
analyzed after 0h, 1h, 3h, 6h, 12h, 24h and 48h of incubation with LPS, TNF-α 
and IL-6, respectively via ELISA. 
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Figure 4-25: TNF-α protein concentration  
 
 Fig. 4-25 show TNF-α protein concentration in the supernatants after 
stimulation with vehicle (blue), 1µg/ml LPS (green), 10ng/ml TNF-α (yellow) and 
10ng / ml IL-6 (pink) for up to 48 hours. IGF concentrations in supernatants are 
shown as the x-fold change in relation to 0h. Data are shown as mean ± SD (* 
p<0.05 and ** p<0.01, vs. 0h, n=3). 
 
As expected TNF-α concentration in the supernatant increased after its 
addition 25-fold after 1h (p<0.01), 31-fold after 3h (p<0.01), 25-fold after 6h 
(p<0.01), and 22-fold after 12h (p<0.05), respectively. After 24h and 48h TNF-α 
levels tended to normalize.  
TNF-α concentration was sparely detectable in control cells as well as after 
LPS and IL-6 stimulation. 
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4.3.2  Determination of IL-6  
 
The concentration of the IL-6 protein in the cell culture supernatants was 
analyzed after 0h, 12h, 24h and 48h of incubation with LPS, TNF-α and IL-6, 
respectively via ELISA.  
 
Figure 4-26: IL-6 protein concentration  
 
Fig. 4-26 shows IL-6 protein concentration in the supernatants after 
stimulation with vehicle (blue), 1µg/ml LPS (green), 10ng/ml TNF-α (yellow) and 
10ng / ml IL-6 (pink) for up to 48 hours. IGF concentrations in supernatants are 
shown as the x-fold change in relation to 0h. Data are shown as mean ± SD (** 
p<0.01 and *** p<0.001 vs. 0h, n=4).  
After adding IL-6, the concentration is high after 12h, 24h and 48h of 
incubation, showing a slight but not significant tendency to drop.   
IL-6 concentration was not changed in the control group as well as after LPS 
and TNF-α incubation. 
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5 DISCUSSION 
 
5.1 Gene expression during differentiation 
 
During the development of myotubes out of myoblasts, the expression levels 
of the myogenic marker genes MyoD and Myogenin are indicators for the quality 
of the cell culture model, as it determines the grade of the myoblast 
differentiation. 
In our trials, the observation of the myogenic marker gene expression levels 
showed the expected results. Due to the developmental state of the 
undifferentiated myoblasts, the transcription level of MyoD was already at a high 
range, showing almost the same expression level before and after differentiation. 
The myogenin expression increased in a later cell determination phase, so in the 
myoblasts we were able to detect it only in very small amounts, whereas after 
differentiation the myogenin level increases. These results correlate with earlier 
findings concerning differentiation-dependent expression of skeletal muscle 
marker genes, where MyoD is described to be already at a high level in 
myoblasts, whereas myogenin expression increases significantly during 
differentiation (Rudnicki and Jaenisch, 1995) (Tapscott, 2005).  
According to the MyoD/myogenin marker gene expression levels the C2C12 
cells can be allocated to a certain differentiation state and serve therefore as a 
verification of our cell culture model indicating that the cells are in the desired 
differentiation state.  
As it is already described in literature, a high IGF-1 expression correlates with 
an increase in muscle load (Goldspink, 2006). In our trials, we examined the 
different splicing variants of IGF-1 before and after differentiation. We were able 
to report a significant up regulation of IGF-1Ea and MGF expression levels. An in 
vivo study of the expression of IGF-1 splicing variants following acute muscle 
damage showed similar results in the muscle regeneration phase. They suggest 
a role for MGF in the activation / proliferation phase marked by an up-regulation 
of MyoD. IGF-1Ea and -Eb seem to be related to the myogenic differentiation 
program marked by an increase in myogenin (McKay et al., 2008). The results 
after a transfection of a muscle cell line with MGF or IGF-1Ea supported these 
suggestions (Philippou et al., 2007).  
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IGF-1Ea was shown in literature to promote terminal differentiation and 
myotube formation (Yang and Goldspink, 2002) (Hill and Goldspink, 2003). The 
findings concerning MGF and IGF-1Ea correlate with our results, however we 
were not able to determine a time-point-related difference of MGF and IGF-1Ea 
expression. Also the correlation between MGF and MyoD could not be detected. 
This difference might be cell culture-related, as due to our knowledge this is the 
first study analyzing the different IGF-1 splicing variants in C2C12 cells.    
IGF-1Eb is the IGF-1 splicing variant with the most unknown function. It is 
mentioned only a few times in literature in connection with skeletal muscle 
differentiation. Taking our results, in contrast to IGF-1Ea and MGF, this splicing 
variant interestingly seems to be expressed already in the proliferating myoblasts 
and its expression level doesn’t change during differentiation. Therefore we 
suggest that IGF-1Eb could be an earlier regulator in muscle cell differentiation. 
However, our results differ from the findings mentioned above, where IGF-1Eb is 
described to be up-regulated together with IGF-1Ea in connection with myogenic 
differentiation (McKay et al., 2008). This might be an in vitro – in vivo or cell 
culture model related difference, as due to our knowledge an up-regulation of 
IGF-1Eb during differentiation is not described for C2C12 cells so far.  
Muscle specific miRNA are, as their name says, expected to be expressed in 
muscle cells. For all muscle specific miRNAs we analyzed, except miRNA-499, 
we detected a significant increase during differentiation.  
The muscle specific miRNAs showed an impacting up regulation for up to 
more than 400 fold for miRNA-1 and miRNA-133a. These two miRNAs are 
proven to be encoded in one transcriptional locus which means that they are 
transcribed together (Chen et al., 2006), (Zhao et al., 2005). This theory is 
underlined with our results, as the level of up regulation of miRNA-1 and miRNA-
133a tend to be almost the same.  
The expression level of miRNA-133b and -206 increased during differentiation 
significantly, but with a lower extent. This is a consequence of the higher 
expression rate of these miRNAs already in the myoblasts, so that the x-fold up 
regulation is lower.  
A significant increase of miRNA-133, -1 and -206 during differentiation was 
already described in literature (Rao et al., 2006) (Kim et al., 2006) (McCarthy and 
Esser, 2007).  
Recent findings describe a significant up-regulation of miRNA-499 during 
differentiation (McCarthy et al., 2009). In our trials this miRNA shows the 
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tendency to increase during differentiation; however the up-regulation is not 
significant, due to the very high standard deviation, which might be a result of the 
low general expression level we detected for this miRNA. The acting of miRNA-
499 in skeletal muscle remains to be discovered.  
In fact, with our results we can underline the importance of all our analyzed 
muscle specific miRNAs for muscle development. Their up-regulation during the 
differentiation phase is an indicator for their crucial role in skeletal muscle cell 
development and muscle cell differentiation.  
The expression level of the immuno-related miRNA-155 showed the tendency 
to increase during differentiation, however this change wasn’t significant.  A slight 
increase might be the reason of cell treatment during differentiation. Serum 
deprivation is accompanied by stress conditions which might force the cells to 
react over the up-regulation of the immune response.   
 
5.2  Influence of inflammatory stimuli on differentiated 
myotubes 
 
The stimulation of the fully differentiated myotubes with either TNF-α, LPS or 
IL-6 was our in vitro model for simulating an inflammatory state in a muscle 
tissue. Our findings concerning the myogenic marker gene MyoD correspond 
with earlier results, where especially TNF-α was shown to down-regulate the 
expression of MyoD in C2C12 cells (Langen et al., 2004) (Guttridge et al., 2000).  
A decrease of MyoD after TNF-α / LPS treatment to nearly half of the control 
level proofs a strong effect of inflammation on this muscle specific gene. If the 
down-regulation of this important marker gene can be seen as a partial 
dedifferentiation or more as an arrest of certain muscular gene expression due to 
energy conservation under stress conditions, remains to be discovered. The 
assumption, concerning a MyoD mediated up-regulation of miRNA-133, does not 
go confirm with our findings, as MyoD is expressed already in the proliferating 
myoblast. Of course there might be a non direct influence including other signals. 
Also the initially high expression level of miRNA-133b seems to correlate with this 
thesis. Nevertheless the inflammation induced down-regulation of MyoD after 
TNF- α / LPS stimulation, respectively had no impact neither on the expression 
level of miR-133a nor on miRNA-133b. In contrast, we would support a positive 
regulatory effect between MyoD and UCP assumed by the author, as in the 
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context of inflammation, concerning our results, an inflammation induced drop in 
MyoD expression this way would directly influence the fatty acid and energy 
metabolism (Chen et al., 2009).  
We were not able to measure any effect of inflammation on the expression of 
myogenin. In contrast to our findings, a differentially TNF-a induced inhibition of 
myogenin expression was described in C2C12 cells (Layne and Farmer, 1999) 
and a drop of myogenin level in muscle wasting of human cachexia 
(Ramamoorthy et al., 2009). Due to the general down-regulation of myogenin 
expression occurring in our trials after 0h, a possible decrease after TNF-α / LPS 
/ IL-6 treatment might be overlaid and therefore not detectable. We suggest that 
the negative effect on myogenin expression after 0h might be primarily a result of 
a stress reaction after the media switch directly before stimulation. As for the 
other genes we could not observe such a long lasting reaction, we suppose that 
myogenin is especially sensitive to environmental signals. This theory is also 
supported by findings showing that myogenin, but not MyoD expression, is 
negatively regulated in C2C12 cells when they are exposed to low temperatures 
(Shima and Matsuda, 2008). While after LPS and IL-6 incubation as well as for 
the control myogenin expression returned to basic levels 48h after stimulation, 
TNF-α treated cells showed a significant drop in myogenin expression until the 
end of the time kinetics. This might be an indicator for a possible negative 
influence of TNF-α to the recovery mechanisms of skeletal muscle tissue.  
As for MyoD, we also could detect an impacting decrease of mRNA 
expression levels of the two splicing variants IGF-1Ea and MGF to almost a third 
compared to the control. Both of them showed a similar down regulation curve 
after TNF-α incubation. As the importance of IGF-1 for muscle metabolism lies in 
increasing protein synthesis and inhibition of protein proteolysis, its down-
regulation in stress conditions as inflammation seems to be necessary for the 
conservation of energy. Down-regulation of IGF-1 after TNF-α treatment was 
already described in literature. TNF-α is known to inhibit IGF-1 gene and protein 
expression (Fernandez-Celemin et al., 2002). We also detected a reduced 
increase of IGF-1 protein expression after 48h of TNF-α incubation. The drop of 
the IGF-1 gene-expression level seems to be JNK-dependent (Frost and Lang, 
2007). Frost et al. described in experiments with C2C12 myocytes that LPS 
stimulates NF-kB activity, the activation of JNK signalling transduction, as well as 
the increase of NO-synthase 2 (NOS2) in these cells (Frost et al., 2006). Nf-kB is 
thought to promote cell proliferation over stimulation of Cyclin D1, which is 
suggested to inhibit MyoD (Muscat and Dressel, 2000). As LPS stimulates TNF- 
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α expression, the down-regulation of MyoD and IGF-1 we detected after TNF- α 
treatment might therefore be a result of the parallel activation of JNK and NfkB 
signalling.   
The specific reactions of the different IGF-1 splicing variants on TNF- α / LPS 
are not described for skeletal muscle so far. However, an over-expression of IGF-
1Ea was proven to reduce myofibre necrosis in mdx mice (Grounds et al., 2008).  
The IGF-1Eb expression level is, in contrast to IGF-1Ea and MGF not 
influenced by LPS and TNF-α. Surprisingly, it is the only of our analyzed 
parameters which showed a significant down-regulation after IL-6 treatment 
almost throughout the whole time kinetics. Up to our knowledge, this is not 
described in literature so far. Due to these findings we assume a possible role for 
IGF-1Eb in negatively regulating muscle mass maintenance in response to 
inflammation and we suppose this regulation is mediated by the cytokine IL-6.   
Due to our knowledge, the effect of TNF-α / LPS or IL-6 on the expression 
level of the here analyzed miRNAs has not been tested so far. In our trials, none 
of the measured miRNA expression levels changed significantly after incubation 
with TNF-α / LPS or IL-6. Therefore we suggest, that there is no direct connection 
between the here analyzed skeletal muscle specific miRNAs and the 
inflammatory stimuli used in our study. Of course there might be a connection to 
inflammation induced muscle atrophy over other cytokines or not yet discovered 
parameters. Meltzer et.al. observed for example a decreased expression of 
miRNA-1 / -206 and -133a during C2C12 differentiation after TNF-α / IFN-γ 
stimulation (Meltzer et al.). Compared to our data, these findings let us assume 
an influence of inflammation on the initial differentiation steps in myogenesis over 
slowing down the expression rate of muscle specific miRNAs. As we were not 
able to detect a miRNA down-regulation in TNF-α / LPS or IL-6 treated myotubes, 
we suggest that the influence of inflammation on these miRNAs is a non-direct 
one and includes other factors. That suggests a role for the inflammation – 
muscle specific miRNA network in inhibiting de novo protein synthesis more than 
in protein breakdown. Our findings concerning a constant expression of miRNA-1 
and -133a also after stimulation are of great interest when being compared with 
the studies of McCarthy et al. They also describe no change in the expression 
rate of these miRNAs after 7 days of hindlimb suspension. Therefore we support 
their thesis that these miRNAs might be very stable concerning external 
conditions as inflammation or immobility which might also give them a certain role 
in buffering stress conditions and counteracting the dedifferentiation of the 
muscle cell (McCarthy and Esser, 2007).  
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In contrast to miRNA-1 and -133a, a study of Allen et al. describes a decline of 
miRNA-206 after skeletal muscle atrophy occurring 12 days after spaceflight 
(Allen et al., 2009). This let us assume that a possible regulation of this miRNA 
might also occur after inflammation but only after a time period longer than 48h.  
 The recently discovered muscle specific miRNA-208b and -499 are thought to 
play a role in fibre-type transition. In our trials, the amount of miRNA-208b was 
beyond the detection level at all time points. This may be a reason for the in 
general low expression level of miRNA-499 in our trials, due to earlier findings 
where miRNA-208b is described as an up-regulator of miRNA-499 (McCarthy et 
al., 2009). For miRNA-499 we observed a slight tendency to decrease after 48h 
of TNF-α stimulation, but this down-regulation was not at a significant level. 
Therefore we suggest once more, that the time period of measurement might 
have been too short.  
As for the muscle specific miRNAs we couldn’t observe any change in the 
expression for the immuno-related miRNA-155 after stimulation. Therefore the  
TNF-α mediated expression of miRNA-155 already shown in literature, could not 
be repeated in C2C12 cells (Kutty et al., 2011). 
 
5.3 Effectiveness of inflammatory stimuli on C2C12 
cells 
 
In summary, the effects of the here used inflammatory stimuli differ in their 
effectiveness influencing muscular gene expression when being compared.  
Concerning our trials, TNF-α showed the greatest influence on down 
regulating MyoD as well as IGF-1Ea and MGF. The drop of gene expression 
levels of these genes after LPS stimulation was similar to that of TNF-α, however 
the intensity of down regulation was not as strong. Our findings showed clear that 
in C2C12 myotubes, when exposed to the dose with the maximum effect on 
muscular gene expression, the TNF-α stimulation has a more severe influence on 
genes related to muscle wasting than LPS stimulation. It is known that LPS 
induces TNF-α expression in C2C12 cells (Frost et al., 2006), and as far as the 
results are similar, we assume that TNF-α plays the key role in regulation also 
after LPS incubation. However the switch on of TNF-α transcription and 
translation by LPS is a complex mechanism involving not only LPS but also a lot 
of other factors. Frost et al. described a short lived response of TNF-α mRNA 
 - 90 - 
after LPS stimulation. Due to the LPS induced expression of IkB-s, which is an 
NF-kB inhibitor, they suggest that this would have a limiting effect on TNF-α 
mRNA expression. Beside the transcriptional inhibition they also hypothesize the 
involvement of the translational silencer TIA-1 (intracytoplasmic antigen 1), acting 
over binding to the AU-rich elements of the TNF-α mRNA preventing its 
translation. Correlating to our results, no TNF-α protein could be observed in their 
study after LPS stimulation (Frost and Lang, 2008). Both, the suggested 
transcriptional and the translational inhibitory mechanisms, correspond to our 
data and might be the reason for a reduced and controlled LPS induced 
expression of TNF-α and therefore a reduced regulatory effect on its targets.  
Although IL-6 induced muscle wasting is often described in literature, we 
couldn’t detect an influence of IL-6 incubation on any of the here measured 
parameters, accept IGF-1Eb. A performed IL-6 concentration analyzes (data not 
shown) didn’t show an effect either. As the concentration is not the problem, it 
may be the time period of the measurement. We assume that 48h of IL-6 
stimulation may be too short to get a measurable reaction of the cells.  
However, beside the experimental design there might be another reason for 
the constant expression level. Earlier studies as well didn’t find an influence of IL-
6 on protein breakdown rates (Williams et al., 1998). Haddad et al. in contrary 
observed a significant increase in IGF-1 mRNA after IL-6 injection into a rat 
muscle. They suggest this as a compensatory response to the IL-6 induced 
decline in S6K1 phosphorylation they discovered (Bodell et al., 2009). A recent 
study unrolled the importance of IL-6 for the initial growth response during the 
recovery from atrophy (Washington et al.). Taken together, these results show a 
very disperse picture of IL-6 signalling. It seems like IL-6 plays an important role 
in skeletal muscle atrophy / hypertrophy, but the detailed signalling mechanism of 
this pro-inflammatory cytokine remains to be discovered.  
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6 FUTURE ASPECTS 
 
Skeletal muscle tissue is one of the most essential tissues of the human body 
and the attempt of this diploma thesis was to contribute to unroll the mechanisms 
how muscle related genes, inflammation and miRNAs play together in the 
process of muscle wasting.  
In our study we clearly showed, that there is an influence of inflammatory 
conditions, provided by TNF-α and LPS, on muscle specific and growth related 
genes. Although the murine cell culture line C2C12 was used for basic research 
in our trials, we strongly assume, that not only myoblast cell culture cells but also 
muscle tissue is sensitive to these signals and that inflammation might therefore 
be a strong contributor to skeletal muscle atrophy.  
Secondly we proofed that the expression levels of the muscle specific miRNAs 
are almost not affected by the here used inflammatory stimuli within a period of 2 
days. This indicates that these miRNAs are not involved in atrophy processes 
directly related to the inflammation induced down-regulation of MyoD and IGF-1 
splicing variants.   
It needs to be further investigated, if and in which way other miRNAs play a 
role in skeletal muscle atrophy and in which context the down-regulation of MyoD 
and IGF-1 influences the decrease of skeletal muscle mass.  
Another interesting attempt for further investigations could be over the 
observation of miRNA expression in connection with a broader spectrum of 
cytokines and prolonged time kinetics.  
To summarize our results we can say that there is a direct influence of 
inflammation on muscle specific and growth related genes which, so far, seem to 
be independent from the here analyzed miRNAs.  
 - 92 - 
7 ANNEXES 
 
7.1 TE buffer preparation 
 
Materials:  
Na2EDTA2H20, Tris, NaOH and HCl (all purchased by Merck, Darmstadt, 
Germany), 0.2µl filter (Nalgene Nunc International, Rochester, NY), deionized 
water (Milli-Q Ultra Pure Water System, Millipore GmbH, Billerica, MA) 
 
0.1M EDTA:  
Add 3.72g disodium ethylenediaminetetraacetic acid dihydrate (Na2EDTA  
2H2O) to 80ml of deionized water; and stir vigorously until dissolved 
Adjust the pH to 8.0 (+/-0.2) at room temperature with 1N NaOH 
Fill up to 100ml with deionized water and mix 
The solution has to be filter through a 0.2µm Nalgene filter or autoclaved 
Discard after 6 months 
0.1M Tris-HCl: 
Dissolve 12,11g Tris base in 800ml deionized water 
Adjust the pH to 8.0 (+/-0.2) at room temperature with 1N HCl 
Fill up to one liter with deionized water and mix 
The solution has to be filtered through a 0.2µm filter or autoclaved 
Discard after 6 months 
 
TE Buffer 
Mix 100ml of 0.1M Tris-HCl (pH 8.0), 10ml of 0.1M EDTA and 800ml of 
deionized water.  
Adjust to one liter with deionized water and mix 
Autoclave or filter (0,2µm filter), store it in 100ml aliquots and discard after 6  
months 
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7.2 List of abbreviations 
 
AMPK = Adenosin monophosphate kinase 
Cdks = cyclin-dependent kinases 
COPD = chronic obstructive lung disease 
4E-BP1 = 4E-binding protein 
FOXO1 = forkhead box protein 1 
Fstl1 = follistatin-related protein 1 
IGF-1 = insulin-like growth factor 1 
LPS = Lipopolysaccharide 
MHC = Myosin heavy chain 
MRF = myogenic regulatory factors 
MGF = mechanical growth factor 
mTOR = mammalian target of Rapamycin 
MuRF1 = muscle ringfinger 1 
MAFbx = Atrogin 
NFAT = nuclear factor of cativated T-cells 
Nf-kB = nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells 
PDK4 = pyruvate dehydrogenase kinase 4 
PGC-1alpha = peroxisome proliferators-activated receptor-gamma coactivator 
1alpha  
PI3K = phosphoinositid 3 kinase 
PPARdelta = peroxisome proliferators-activated receptor delta 
Pur-beta = Purine-rich element-binding protein B 
Rb = Retinoblastoma protein 
Rheb = Ras homolog enriched in brain 
RISC = RNA-induced scilencing complex  
Sox6 = SRY (sex determining region Y)-box 6 
Thrap1 = Thyroid Hormone Receptor Associated Protein 1  
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TIA-1 = intracytoplasmic antigen 1 
TNF-a = Tumor necrosis factor alpha 
TSC1 / TSC2 = tuberous sclerosis complex -1 and -2 
UCPs = uncoupling proteins 
Utrn = utrophin 
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